: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

COVID-19

Free Subscription

Articles published in Lancet Infect Dis
Retrieve available abstracts of 774 articles:
HTML format

Single Articles

April 2024

BUONSENSO D, Tantisira KG
Long COVID and SARS-CoV-2 persistence: new answers, more questions.
Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00216.
PubMed

ZUO W, He D, Liang C, Du S, et al
The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.
Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00171.
PubMed Abstract available

JIN SL, Kolis J, Parker J, Proctor DA, et al
Social histories of public health misinformation and infodemics: case studies of four pandemics.
Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
PubMed Abstract available

Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
PubMed Abstract available

Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
Lancet Infect Dis. 2024 Apr 15:S1473-3099(24)00176.
PubMed Abstract available

PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
Plasma-based antigen persistence in the post-acute phase of COVID-19.
Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
PubMed

DE MENEZES NEVES PDM, Mohrbacher S, Lobato Vasques I, Barreira Cavalcante L, et al
Renal infarction secondary to Aspergillus spp. embolism following COVID-19.
Lancet Infect Dis. 2024;24:e266-e267.
PubMed

March 2024

LARIVIERE Y, Matuvanga TZ, Osang'ir BI, Milolo S, et al
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised
Lancet Infect Dis. 2024 Mar 26:S1473-3099(24)00058.
PubMed Abstract available

WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1.
Lancet Infect Dis. 2024 Mar 21:S1473-3099(24)00155.
PubMed

DIXIT A, Bennett R, Ali K, Griffin C, et al
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101.
PubMed Abstract available

LI SM, Zhu FC
The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.
Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00157.
PubMed

Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
PubMed Abstract available

ZHANG R, Hung IF
Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.
Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00156.
PubMed

BENNETT C, Woo W, Bloch M, Cheung K, et al
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077.
PubMed Abstract available

BILSEN MP, Conroy SP, Schneeberger C, Platteel TN, et al
A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study.
Lancet Infect Dis. 2024 Mar 5:S1473-3099(23)00778.
PubMed Abstract available

KOUTSAKOS M, Rockman S, Krammer F
Is eradication of influenza B viruses possible?
Lancet Infect Dis. 2024 Mar 4:S1473-3099(24)00132.
PubMed

February 2024

POUKKA E, Auranen K, Baum U
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies.
Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00106.
PubMed

HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply.
Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00107.
PubMed

PLEY C, Kampmann B
Access to respiratory syncytial virus preventive tools for neonates and infants in Europe.
Lancet Infect Dis. 2024 Feb 19:S1473-3099(24)00084.
PubMed

FAFI I, Assad Z, Lenglart L, Valtuille Z, et al
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices.
Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00081.
PubMed

LI Y
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices - Author's reply.
Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00082.
PubMed

MACHKOVECH HM, Hahn AM, Garonzik Wang J, Grubaugh ND, et al
Persistent SARS-CoV-2 infection: significance and implications.
Lancet Infect Dis. 2024 Feb 7:S1473-3099(23)00815.
PubMed Abstract available

MARKING U, Bladh O, Aguilera K, Yang Y, et al
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
Lancet Infect Dis. 2024;24:e80-e81.
PubMed

ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
Lancet Infect Dis. 2024 Feb 1:S1473-3099(24)00060.
PubMed

BERTRAN M, D'Aeth JC, Abdullahi F, Eletu S, et al
Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
Lancet Infect Dis. 2024 Feb 1:S1473-3099(23)00706.
PubMed Abstract available

January 2024

DENNING DW
Global incidence and mortality of severe fungal disease.
Lancet Infect Dis. 2024 Jan 12:S1473-3099(23)00692.
PubMed Abstract available

COSSMANN A, Hoffmann M, Stankov MV, Lurken K, et al
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00783.
PubMed

KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al
Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
PubMed

HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.
Lancet Infect Dis. 2024 Jan 5:S1473-3099(23)00746.
PubMed

KAKU Y, Okumura K, Padilla-Blanco M, Kosugi Y, et al
Virological characteristics of the SARS-CoV-2 JN.1 variant.
Lancet Infect Dis. 2024 Jan 3:S1473-3099(23)00813.
PubMed

December 2023

CONG B, Koc U, Bandeira T, Bassat Q, et al
Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00630.
PubMed Abstract available

ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00650.
PubMed Abstract available

HERFST S, de Vries RD
Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants.
Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00734.
PubMed

MONTGOMERY MP, Morris SE, Rolfes MA, Kittikraisak W, et al
The role of asymptomatic infections in influenza transmission: what do we really know.
Lancet Infect Dis. 2023 Dec 18:S1473-3099(23)00619.
PubMed Abstract available

YANG S, Yu Y, Xu Y, Jian F, et al
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.
Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00744.
PubMed

GANDHI M
Post-viral sequelae of COVID-19 and influenza.
Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
PubMed

XIE Y, Choi T, Al-Aly Z
Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.
Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684.
PubMed Abstract available

RAMAN B, Ramasamy MN
Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?
Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00735.
PubMed

LAU RI, Su Q, Lau ISF, Ching JYL, et al
A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial.
Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00685.
PubMed Abstract available

ZUO F, Cao Y, Sun R, Yisimayi A, et al
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86.
Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00732.
PubMed

CARR EJ, Dowgier G, Greenwood D, Herman LS, et al
SARS-CoV-2 mucosal neutralising immunity after vaccination.
Lancet Infect Dis. 2023 Dec 6:S1473-3099(23)00705.
PubMed

BURKI T
UK Covid-19 Inquiry.
Lancet Infect Dis. 2023;23:e516-e517.
PubMed

BAGCCHI S
Boost for COVID-19 testing in the USA.
Lancet Infect Dis. 2023;23:e514.
PubMed

November 2023

DE LUSIGNAN S, Hobbs FR, Sheikh A
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic.
Lancet Infect Dis. 2023 Nov 28:S1473-3099(23)00736.
PubMed

GOTTLIEB RL, Paredes R
Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19.
Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00633.
PubMed

FAN X, Dai X, Ling Y, Wu L, et al
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00577.
PubMed Abstract available

STANKOV MV, Hoffmann M, Gutierrez Jauregui R, Cossmann A, et al
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
Lancet Infect Dis. 2023 Nov 20:S1473-3099(23)00690.
PubMed

LASSAUNIERE R, Polacek C, Utko M, Sorensen KM, et al
Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1.
Lancet Infect Dis. 2023 Nov 7:S1473-3099(23)00682.
PubMed

JESUDASON T
New licensing agreements for COVID-19.
Lancet Infect Dis. 2023;23:e471.
PubMed

October 2023

OLBRICH L, Verghese VP, Franckling-Smith Z, Sabi I, et al
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
Lancet Infect Dis. 2023 Oct 30:S1473-3099(23)00491.
PubMed Abstract available

SIMPSON CR, Robertson C, McMenamin J, Ritchie LD, et al
Developing the EAVE III platform for future health crises.
Lancet Infect Dis. 2023 Oct 12:S1473-3099(23)00626.
PubMed

GROBUSCH MP, Ruiz Del Portal Luyten C, Visser BJ, de Jong HK, et al
Overcoming publication and dissemination bias in infectious diseases clinical trials.
Lancet Infect Dis. 2023 Oct 11:S1473-3099(23)00455.
PubMed Abstract available

WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand.
Lancet Infect Dis. 2023 Oct 6:S1473-3099(23)00620.
PubMed

FAUST JS
The therapeutic validation of long COVID.
Lancet Infect Dis. 2023;23:1096-1097.
PubMed

September 2023

BRAMANTE C
The power and pressure placed on clinicians and guideline panels.
Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00557.
PubMed

SCHILLING WHK, Jittamala P, Watson JA, Boyd S, et al
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00493.
PubMed Abstract available

ONYWERA H, Ondoa P, Nfii F, Ogwell A, et al
Boosting pathogen genomics and bioinformatics workforce in Africa.
Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00394.
PubMed Abstract available

SHEWARD DJ, Yang Y, Westerberg M, Oling S, et al
Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.
Lancet Infect Dis. 2023 Sep 27:S1473-3099(23)00588.
PubMed

YANG S, Yu Y, Jian F, Song W, et al
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.
Lancet Infect Dis. 2023 Sep 19:S1473-3099(23)00573.
PubMed

URIU K, Ito J, Kosugi Y, Tanaka YL, et al
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
Lancet Infect Dis. 2023 Sep 18:S1473-3099(23)00575.
PubMed

BLOM K, Fjallstrom P, Molnar C, Aberg M, et al
SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters.
Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00548.
PubMed

ZHANG L, Kempf A, Nehlmeier I, Cossmann A, et al
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3.
Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00547.
PubMed

KAKU Y, Kosugi Y, Uriu K, Ito J, et al
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00553.
PubMed

WANG Q, Guo Y, Zhang RM, Ho J, et al
Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.
Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00555.
PubMed

August 2023

MARANDA B, Labbe SM, Lurquin M, Brabant P, et al
Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00393.
PubMed Abstract available

WANG Y, Cao B
The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases.
Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00454.
PubMed

ABO YN, Jamrozik E, McCarthy JS, Roestenberg M, et al
Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy.
Lancet Infect Dis. 2023 Aug 10:S1473-3099(23)00294.
PubMed Abstract available

GRANT R, Benamouzig D, Catton H, Cheng VC, et al
COVID-19 pandemic: a catalyst for accelerating global action on patient safety.
Lancet Infect Dis. 2023 Aug 9:S1473-3099(23)00485.
PubMed

TAN CY, Chiew CJ, Pang D, Lee VJ, et al
Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
Lancet Infect Dis. 2023 Aug 2:S1473-3099(23)00373.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
Where are the long COVID trials?
Lancet Infect Dis. 2023;23:879.
PubMed

July 2023

MADHI SA, Feikin DR
Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19?
Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00425.
PubMed

MATEO-URDIALES A, Sacco C, Fotakis EA, Del Manso M, et al
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00374.
PubMed Abstract available

COHN H, Bloom N, Cai GY, Clark JJ, et al
Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
Lancet Infect Dis. 2023 Jul 17:S1473-3099(23)00352.
PubMed Abstract available

CERQUEIRA-SILVA T, Boaventura VS, Barral-Netto M
Effectiveness of monovalent and bivalent COVID-19 vaccines.
Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00379.
PubMed

KIRSEBOM FCM, Andrews N, Stowe J, Ramsay M, et al
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00365.
PubMed Abstract available

SCHAEFER GO, Atuire CA, Kaur S, Parker M, et al
The importance of getting the ethics right in a pandemic treaty.
Lancet Infect Dis. 2023 Jul 5:S1473-3099(23)00364.
PubMed Abstract available

AL-ALY Z
Prevention of long COVID: progress and challenges.
Lancet Infect Dis. 2023;23:776-777.
PubMed

CARR EJ, Wu MY, Gahir J, Harvey R, et al
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
Lancet Infect Dis. 2023;23:781-784.
PubMed

June 2023

NAKAKUBO S, Kishida N, Okuda K, Kamada K, et al
Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00271.
PubMed Abstract available

TSUZUKI S
The future of COVID-19 surveillance in Japan.
Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00292.
PubMed

CRODA J
Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges.
Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00363.
PubMed

LI JX, Hou LH, Gou JB, Yin ZD, et al
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00350.
PubMed Abstract available

SOLERA JT, Ierullo M, Arbol BG, Mavandadnejad F, et al
Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.
Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00357.
PubMed

YAMIN D, Yechezkel M, Arbel R, Beckenstein T, et al
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00207.
PubMed Abstract available

MADHI SA, Izu A
Safety of COVID-19 booster dose: is the juice worth the squeeze?
Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00296.
PubMed

LEE IT, Cosgrove CA, Moore P, Bethune C, et al
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00295.
PubMed Abstract available

SHANG L, Cao B
Adapted vaccine strategy: facing the persistent challenges of COVID-19.
Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00370.
PubMed

LIN DY, Xu Y, Gu Y, Zeng D, et al
Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lancet Infect Dis. 2023 Jun 16:S1473-3099(23)00272.
PubMed Abstract available

BRAMANTE CT, Buse JB, Liebovitz DM, Nicklas JM, et al
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Lancet Infect Dis. 2023 Jun 8:S1473-3099(23)00299.
PubMed Abstract available

WALIA K, Mendelson M, Kang G, Venkatasubramanian R, et al
How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00124.
PubMed Abstract available

ALAKIJA A
Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats.
Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00279.
PubMed Abstract available

KANA BD, Arbuthnot P, Botwe BK, Choonara YE, et al
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
Lancet Infect Dis. 2023 Jun 5:S1473-3099(22)00878.
PubMed Abstract available

May 2023

ZHANG R, Hung IF
CS-2034 mRNA vaccine: a new option for COVID-19 infection?
Lancet Infect Dis. 2023 May 19:S1473-3099(23)00277.
PubMed

WU JD, Li JX, Liu J, Wang HM, et al
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged >/=18 years: a randomised, double-blind, phase 2b trial.
Lancet Infect Dis. 2023 May 19:S1473-3099(23)00199.
PubMed Abstract available

BHATIA S, Imai N, Watson OJ, Abbood A, et al
Lessons from COVID-19 for rescalable data collection.
Lancet Infect Dis. 2023 May 4:S1473-3099(23)00121.
PubMed Abstract available

LEE NR, King A, Vigil D, Mullaney D, et al
Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future.
Lancet Infect Dis. 2023 May 3:S1473-3099(23)00190.
PubMed Abstract available

YAMASOBA D, Uriu K, Plianchaisuk A, Kosugi Y, et al
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
Lancet Infect Dis. 2023 May 3:S1473-3099(23)00278.
PubMed

IZU A, Nunes MC, Solomon F, Baillie V, et al
All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200.
PubMed Abstract available

LEVY C, Cohen R
Infectious diseases in the COVID-19 era: gaps between countries.
Lancet Infect Dis. 2023 May 1:S1473-3099(23)00198.
PubMed

April 2023

JUAN-GINER A, Namulwana ML, Kimathi D, Grantz KH, et al
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Lancet Infect Dis. 2023 Apr 28:S1473-3099(23)00131.
PubMed Abstract available

MONACH PA, Branch-Elliman W
More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.
Lancet Infect Dis. 2023 Apr 26:S1473-3099(23)00274.
PubMed

VASIN AV, Stukova MA
Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2.
Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00189.
PubMed

TAN NH, Geers D, Sablerolles RSG, Rietdijk WJR, et al
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00140.
PubMed Abstract available

STOLIAROFF-PEPIN A, Harder T
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations.
Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00187.
PubMed

ARBEL R, Peretz A, Sergienko R, Friger M, et al
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00122.
PubMed Abstract available

JENKIN D, Wright D, Folegatti PM, Platt A, et al
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Lancet Infect Dis. 2023 Apr 12:S1473-3099(23)00068.
PubMed Abstract available

SOLERA JT, Arbol BG, Ferreira VH, Kurtesi A, et al
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.
Lancet Infect Dis. 2023 Apr 5:S1473-3099(23)00208.
PubMed

IWASAKI A, Putrino D
Why we need a deeper understanding of the pathophysiology of long COVID.
Lancet Infect Dis. 2023;23:393-395.
PubMed

URAKI R, Ito M, Kiso M, Yamayoshi S, et al
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
Lancet Infect Dis. 2023;23:402-403.
PubMed

March 2023

WANG Q, Bowen A, Tam AR, Valdez R, et al
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
Lancet Infect Dis. 2023 Mar 29:S1473-3099(23)00181.
PubMed

EYRE DW, Futschik M, Tunkel S, Wei J, et al
Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00129.
PubMed Abstract available

PRESTEDGE J, Williamson DA
The performance of rapid antigen tests against SARS-CoV-2 variants.
Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00186.
PubMed

WILKINS D, Langedijk AC, Lebbink RJ, Morehouse C, et al
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
Lancet Infect Dis. 2023 Mar 17:S1473-3099(23)00062.
PubMed Abstract available

LEWNARD JA, McLaughlin JM, Malden D, Hong V, et al
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lancet Infect Dis. 2023 Mar 15:S1473-3099(23)00118.
PubMed Abstract available

TAN CY, Chiew CJ, Pang D, Lee VJ, et al
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00060.
PubMed Abstract available

BOYTON RJ, Altmann DM
Imprinted hybrid immunity against XBB reinfection.
Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00138.
PubMed

CHEMAITELLY H, Ayoub HH, Tang P, Coyle P, et al
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
Lancet Infect Dis. 2023 Mar 10:S1473-3099(23)00058.
PubMed Abstract available

URAKI R, Ito M, Kiso M, Yamayoshi S, et al
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00132.
PubMed

KUIKEN T, Fouchier RAM, Koopmans MPG
Being ready for the next influenza pandemic?
Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00117.
PubMed

KIRBY T
Alemka Markotic-from hantavirus to COVID-19.
Lancet Infect Dis. 2023;23:292.
PubMed

SOTO-RIFO R
Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4.
Lancet Infect Dis. 2023;23:262-263.
PubMed

February 2023

HUANG J, Zhao S, Chong KC, Zhou Y, et al
Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen.
Lancet Infect Dis. 2023 Feb 17:S1473-3099(23)00112.
PubMed

WONG CKH, Lau KTK, Au ICH, Lau EHY, et al
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
Lancet Infect Dis. 2023 Feb 13:S1473-3099(22)00873.
PubMed Abstract available

PETROSILLO N
SARS-CoV-2 rebound with and without antivirals.
Lancet Infect Dis. 2023 Feb 13:S1473-3099(23)00063.
PubMed

AGGARWAL NR, Molina KC, Beaty LE, Bennett TD, et al
Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00011.
PubMed Abstract available

WONG CKH, Lau KTK, Leung GM
Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.
Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00056.
PubMed

YUE C, Song W, Wang L, Jian F, et al
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
Lancet Infect Dis. 2023 Feb 3:S1473-3099(23)00010.
PubMed

CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents.
Lancet Infect Dis. 2023 Feb 1:S1473-3099(23)00005.
PubMed

January 2023

URIU K, Ito J, Zahradnik J, Fujita S, et al
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
Lancet Infect Dis. 2023 Jan 31:S1473-3099(23)00051.
PubMed

HOEHL S, Ciesek S
Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00007.
PubMed

HE G, Jones JA, Sun W
COVID-19 travel policies for people from China and discrimination.
Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00052.
PubMed

GIACOBBE DR, Bassetti M
Too many antibiotics for patients with COVID-19 despite low bacterial infections.
Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00866.
PubMed

CHEN JZ, Hoang HL, Yaskina M, Kabbani D, et al
Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.
Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00832.
PubMed Abstract available

BOAVENTURA VS, Cerqueira-Silva T, Barral-Netto M
The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era.
Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00880.
PubMed

BOBROVITZ N, Ware H, Ma X, Li Z, et al
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00801.
PubMed Abstract available

FADLYANA E, Setiabudi D, Kartasasmita CB, Putri ND, et al
Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial
Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00800.
PubMed Abstract available

MARKING U, Bladh O, Havervall S, Svensson J, et al
7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.
Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00834.
PubMed

NILLES EJ, Paulino CT, de St Aubin M, Duke W, et al
Tracking immune correlates of protection for emerging SARS-CoV-2 variants.
Lancet Infect Dis. 2023 Jan 11:S1473-3099(23)00001.
PubMed

BRADY OJ, Hofmann B, Colon-Gonzalez FJ, Gibb R, et al
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting.
Lancet Infect Dis. 2023 Jan 6:S1473-3099(23)00003.
PubMed

ARORA P, Cossmann A, Schulz SR, Ramos GM, et al
Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.
Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00831.
PubMed

MALATO J, Ribeiro RM, Fernandes E, Leite PP, et al
Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months.
Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00833.
PubMed

December 2022

NACHEGA JB, Nsanzimana S, Rawat A, Wilson LA, et al
Advancing detection and response capacities for emerging and re-emerging pathogens in Africa.
Lancet Infect Dis. 2022 Dec 20:S1473-3099(22)00723.
PubMed Abstract available

TSALIK EL, Rouphael NG, Sadikot RT, Rodriguez-Barradas MC, et al
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial.
Lancet Infect Dis. 2022 Dec 13:S1473-3099(22)00735.
PubMed Abstract available

TSANG NNY, So HC, Cowling BJ, Leung GM, et al
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Lancet Infect Dis. 2022 Dec 12:S1473-3099(22)00732.
PubMed Abstract available

BRYANT OK, Man KKC, Jani YH, Wong ICK, et al
Antibiotic prescribing in general practice during COVID-19 and beyond.
Lancet Infect Dis. 2022 Dec 7:S1473-3099(22)00814.
PubMed

HOFFMANN M, Behrens GMN, Arora P, Kempf A, et al
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation.
Lancet Infect Dis. 2022 Dec 5:S1473-3099(22)00792.
PubMed

FLORENTINO PTV, Alves FJO, Cerqueira-Silva T, de Araujo Oliveira V, et al
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil.
Lancet Infect Dis. 2022;22:1669-1670.
PubMed

DEN HARTOG G, van Kasteren PB, Schepp RM, Teirlinck AC, et al
Decline of RSV-specific antibodies during the COVID-19 pandemic.
Lancet Infect Dis. 2022 Dec 1:S1473-3099(22)00763.
PubMed

November 2022

POWELL AA, Kirsebom F, Stowe J, Ramsay ME, et al
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-neg
Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00729.
PubMed Abstract available

IRVING SA, Buchan SA
Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination.
Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00759.
PubMed

ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.
Lancet Infect Dis. 2022 Nov 18:S1473-3099(22)00733.
PubMed

LINDHOLM DA, Kalil AC
Deja vu all over again? Monkeypox and the urgent need for randomised controlled trials.
Lancet Infect Dis. 2022 Nov 15. pii: S1473-3099(22)00722.
PubMed Abstract available

KENNEDY RB
Monkeypox infection creates immune signatures of disease progression.
Lancet Infect Dis. 2022 Nov 7. pii: S1473-3099(22)00691.
PubMed

NICHOLS RM, Deveau C, Upadhyaya H
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic.
Lancet Infect Dis. 2022;22:1531.
PubMed

October 2022

WANG Q, Li Z, Ho J, Guo Y, et al
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00694.
PubMed

ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages.
Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00693.
PubMed

PRENDECKI M, Willicombe M
SARS-CoV-2 vaccine strategies in kidney transplant recipients.
Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00666.
PubMed

KHO MML, Messchendorp AL, Frolke SC, Imhof C, et al
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00650.
PubMed Abstract available

DORON S, Gandhi M
New boosters are here! Who should receive them and when?
Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00688.
PubMed

TARTOF SY, Slezak JM, Puzniak L, Hong V, et al
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.
Lancet Infect Dis. 2022 Oct 25. pii: S1473-3099(22)00692.
PubMed

MADHI SA, Kwatra G, Richardson SI, Koen AL, et al
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis. 2022 Oct 20. pii: S1473-3099(22)00596.
PubMed Abstract available

STANDING JF, Agyeman AA
Learning and confirming in publicly funded antiviral trials.
Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00665.
PubMed

KHOO SH, FitzGerald R, Saunders G, Middleton C, et al
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00644.
PubMed Abstract available

HANSEN CH, Friis NU, Bager P, Stegger M, et al
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
Lancet Infect Dis. 2022 Oct 18. pii: S1473-3099(22)00595.
PubMed Abstract available

ANGELO KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, et al
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
Lancet Infect Dis. 2022 Oct 7. pii: S1473-3099(22)00651.
PubMed Abstract available

LLEWELYN MJ, Budgell EP, Laskawiec-Szkonter M, Cross ELA, et al
Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.
Lancet Infect Dis. 2022 Oct 4. pii: S1473-3099(22)00508.
PubMed Abstract available

RANSCOMBE P
Dr Hammond's COVID-19 inquiry.
Lancet Infect Dis. 2022;22:1433.
PubMed

September 2022

CHIEW CJ, Premikha M, Chong CY, Wei WE, et al
Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
Lancet Infect Dis. 2022 Sep 28. pii: S1473-3099(22)00573.
PubMed Abstract available

JIAN F, Yu Y, Song W, Yisimayi A, et al
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
PubMed

MAITEKI-SEBUGUZI C, Gonahasa S, Kamya MR, Katureebe A, et al
Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign.
Lancet Infect Dis. 2022 Sep 26. pii: S1473-3099(22)00469.
PubMed Abstract available

BANDYOPADHYAY AS, Zipursky S
A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.
Lancet Infect Dis. 2022 Sep 23. pii: S1473-3099(22)00582.
PubMed Abstract available

CARAZO S, Skowronski DM, Brisson M, Barkati S, et al
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00578.
PubMed Abstract available

HUI DS
Hybrid immunity and strategies for COVID-19 vaccination.
Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00640.
PubMed

ARORA P, Nehlmeier I, Kempf A, Cossmann A, et al
Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.
Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00591.
PubMed

POLAND GA, Kennedy RB, Tosh PK
Prevention of monkeypox with vaccines: a rapid review.
Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00574.
PubMed Abstract available

HARDT K, Vandebosch A, Sadoff J, Le Gars M, et al
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Infect Dis. 2022 Sep 13. pii: S1473-3099(22)00506.
PubMed Abstract available

AMIR O, Goldberg Y, Mandel M, Bar-On YM, et al
Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00527.
PubMed Abstract available

IRVING SA, Klein NP
COVID-19 vaccination protects children and adolescents.
Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00575.
PubMed

GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage.
Lancet Infect Dis. 2022 Sep 6. pii: S1473-3099(22)00580.
PubMed

LAZARUS R, Querton B, Corbic Ramljak I, Dewasthaly S, et al
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00502.
PubMed Abstract available

GEURTSVANKESSEL CH, de Vries RD
Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00517.
PubMed

BARDSLEY M, Morbey RA, Hughes HE, Beck CR, et al
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study.
Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00525.
PubMed Abstract available

BILLARD MN, Bont LJ
Quantifying the RSV immunity debt following COVID-19: a public health matter.
Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00544.
PubMed

August 2022

WELLS CR, Galvani AP
Tackling the politicisation of COVID-19 data reporting through open access data sharing.
Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00505.
PubMed

DONG E, Ratcliff J, Goyea TD, Katz A, et al
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned.
Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00434.
PubMed Abstract available

AABY P, Netea MG, Benn CS
Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.
Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00498.
PubMed Abstract available

GAVRIILAKI E, Kokoris S
COVID-19 sequelae: can long-term effects be predicted?
Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00529.
PubMed

PERICO N, Cortinovis M, Suter F, Remuzzi G, et al
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.
Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00433.
PubMed Abstract available

DEUEL JW, Lauria E, Lovey T, Zweifel S, et al
Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo).
Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00449.
PubMed Abstract available

ZAREBSKA-MICHALUK D, Flisiak R
Early oral antiviral use in patients hospitalised with COVID-19.
Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00522.
PubMed

WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00507.
PubMed Abstract available

HALFORD F, Nash S, Tessier E, Kall M, et al
Variation in reported SARS-CoV-2 cases after testing policy changes.
Lancet Infect Dis. 2022 Aug 23. pii: S1473-3099(22)00572.
PubMed

FAUST JS, Renton B, Chen AJ, Du C, et al
Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state.
Lancet Infect Dis. 2022 Aug 22. pii: S1473-3099(22)00547.
PubMed

FRANCO-PAREDES C, Rodriguez-Morales AJ, Henao-Martinez AF, Carrasco P, et al
The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era.
Lancet Infect Dis. 2022 Aug 16. pii: S1473-3099(22)00548.
PubMed

ELLINGTON S, Olson CK
Safety of mRNA COVID-19 vaccines during pregnancy.
Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00443.
PubMed

SADARANGANI M, Soe P, Shulha HP, Valiquette L, et al
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00426.
PubMed Abstract available

MALLORY RM, Formica N, Pfeiffer S, Wilkinson B, et al
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00420.
PubMed Abstract available

RYCKMAN T, Robsky K, Cilloni L, Zawedde-Muyanja S, et al
Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.
Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00500.
PubMed Abstract available

FLORENTINO PTV, Millington T, Cerqueira-Silva T, Robertson C, et al
Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
Lancet Infect Dis. 2022 Aug 8. pii: S1473-3099(22)00451.
PubMed Abstract available

MARTIN GE, Taiaroa G, Taouk ML, Savic I, et al
Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices.
Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00512.
PubMed

July 2022

MCMENAMIN ME, Nealon J, Lin Y, Wong JY, et al
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
Lancet Infect Dis. 2022 Jul 15. pii: S1473-3099(22)00345.
PubMed Abstract available

SUN F, Lin Y, Wang X, Gao Y, et al
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
Lancet Infect Dis. 2022 Jul 14. pii: S1473-3099(22)00430.
PubMed

HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
PubMed Abstract available

FOCOSI D, McConnell S, Casadevall A, Cappello E, et al
Monoclonal antibody therapies against SARS-CoV-2.
Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00311.
PubMed Abstract available

GOTTLIEB RL, Razonable RR
Stewardship of COVID-19 volunteers by nested trial design.
Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00429.
PubMed

BALAKRISHNAN VS
2 years of the Access to COVID-19 Tools-Accelerator.
Lancet Infect Dis. 2022;22:948.
PubMed

SPANER C, Goubran M, Setiadi A, Chen LYC, et al
COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes.
Lancet Infect Dis. 2022;22:937-938.
PubMed

June 2022

ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.
Lancet Infect Dis. 2022 Jun 28. pii: S1473-3099(22)00422.
PubMed

LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled tr
Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00272.
PubMed Abstract available

MARIATULQABTIAH AR, Buttigieg KR
COVID-19 vaccinations for children.
Lancet Infect Dis. 2022 Jun 24. pii: S1473-3099(22)00414.
PubMed

WELLS CR, Galvani AP
The global impact of disproportionate vaccination coverage on COVID-19 mortality.
Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00417.
PubMed

WATSON OJ, Barnsley G, Toor J, Hogan AB, et al
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00320.
PubMed Abstract available

HIGDON MM, Baidya A, Walter KK, Patel MK, et al
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant.
Lancet Infect Dis. 2022 Jun 22. pii: S1473-3099(22)00409.
PubMed

VADREVU KM, Reddy S, Jogdand H, Ganneru B, et al
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
Lancet Infect Dis. 2022 Jun 16. pii: S1473-3099(22)00307.
PubMed Abstract available

BLOM K, Marking U, Havervall S, Norin NG, et al
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.
Lancet Infect Dis. 2022 Jun 9. pii: S1473-3099(22)00362.
PubMed

YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
PubMed

USHER AD
FIND documents dramatic reduction in COVID-19 testing.
Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00376.
PubMed

MONGE S, Rojas-Benedicto A, Olmedo C, Mazagatos C, et al
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00292.
PubMed Abstract available

ADER F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, et al
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.
Lancet Infect Dis. 2022;22:764-765.
PubMed

BRADY OJ, Tian H
Additional considerations for assessing COVID-19 impact on dengue transmission - Authors' reply.
Lancet Infect Dis. 2022;22:763.
PubMed

YEK C, Pacheco AR, Lon C, Leang R, et al
Additional considerations for assessing COVID-19 impact on dengue transmission.
Lancet Infect Dis. 2022;22:762-763.
PubMed

May 2022

TRAEGER MW, Guy R, Asselin J, Patel P, et al
Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
PubMed Abstract available

KIRSEBOM FCM, Andrews N, Stowe J, Toffa S, et al
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
Lancet Infect Dis. 2022 May 24. pii: S1473-3099(22)00309.
PubMed

BURN E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, et al
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.
Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00223.
PubMed Abstract available

WHITELEY W, Wood A
Risk of arterial and venous thromboses after COVID-19.
Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00314.
PubMed

LOUBET P, Launay O
What a second booster dose of mRNA COVID-19 vaccines tells us.
Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00282.
PubMed

MUNRO APS, Feng S, Janani L, Cornelius V, et al
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomis
Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00271.
PubMed Abstract available

ROMERO-OLMEDO AJ, Schulz AR, Hochstatter S, Gupta DD, et al
Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years.
Lancet Infect Dis. 2022;22:588-589.
PubMed

SANCHEZ L, Oviedo Rouco S, Pifano M, Ojeda DS, et al
Antibody durability at 1 year after Sputnik V vaccination.
Lancet Infect Dis. 2022;22:589-590.
PubMed

April 2022

ODONE A, Vigezzi GP, Baldanti F
Implications of COVID-19 vaccine effectiveness waning for public health.
Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00233.
PubMed

ADLHOCH C, Gomes HC
Sustainability of surveillance systems for SARS-CoV-2.
Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00174.
PubMed

SHEIKH A, Kerr S, Woolhouse M, McMenamin J, et al
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.
Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00141.
PubMed Abstract available

BAGER P, Wohlfahrt J, Bhatt S, Stegger M, et al
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00154.
PubMed Abstract available

SMOLENOV I, Han HH, Li P, Baccarini C, et al
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00144.
PubMed Abstract available

LI JX, Zhu FC
The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2.
Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00162.
PubMed

LORTHE E, Bellon M, Berthelot J, Michielin G, et al
A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland.
Lancet Infect Dis. 2022 Apr 14. pii: S1473-3099(22)00267.
PubMed

CRAWSHAW AF, Farah Y, Deal A, Rustage K, et al
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review.
Lancet Infect Dis. 2022 Apr 13. pii: S1473-3099(22)00066.
PubMed Abstract available

ARORA P, Zhang L, Rocha C, Sidarovich A, et al
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3.
Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(22)00224.
PubMed

WANG B, Giles L, Andraweera P, McMillan M, et al
Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(21)00754.
PubMed Abstract available

MENNI C, May A, Polidori L, Louca P, et al
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Lancet Infect Dis. 2022 Apr 8. pii: S1473-3099(22)00146.
PubMed Abstract available

MUTHU V, Agarwal R, Patel A, Kathirvel S, et al
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.
Lancet Infect Dis. 2022 Apr 4. pii: S1473-3099(22)00124.
PubMed Abstract available

KIRBY T
Kanta Subbarao-confronting influenza and COVID-19.
Lancet Infect Dis. 2022;22:460.
PubMed

BURKI T
Hong Kong's fifth COVID-19 wave-the worst yet.
Lancet Infect Dis. 2022;22:455-456.
PubMed

THIRUVENGADAM R, Awasthi A, Bhatnagar S, Garg PK, et al
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply.
Lancet Infect Dis. 2022;22:447.
PubMed

CHAKRABARTI S, Chakrabarti SS, Chandan G, Kaur U, et al
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India.
Lancet Infect Dis. 2022;22:446-447.
PubMed

DYSON L
Modelling results on the impact of COVID-19 testing in schools.
Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00163.
PubMed

COLOSI E, Bassignana G, Contreras DA, Poirier C, et al
Screening and vaccination against COVID-19 to minimise school closure: a modelling study.
Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00138.
PubMed Abstract available

March 2022

NORDSTROM P, Ballin M, Nordstrom A
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00143.
PubMed Abstract available

GARG PK, Thiruvengadam R
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world.
Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00207.
PubMed

TAN HX, Juno JA
Interplay of infection and vaccination in long-term protection from COVID-19.
Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00210.
PubMed

CERQUEIRA-SILVA T, Andrews JR, Boaventura VS, Ranzani OT, et al
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00140.
PubMed Abstract available

DAL-RE R, Becker SL, Bottieau E, Holm S, et al
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
Lancet Infect Dis. 2022 Mar 29. pii: S1473-3099(22)00119.
PubMed Abstract available

POWELL AA, Kirsebom F, Stowe J, McOwat K, et al
Effectiveness of BNT162b2 against COVID-19 in adolescents.
Lancet Infect Dis. 2022 Mar 21. pii: S1473-3099(22)00177.
PubMed

SHEWARD DJ, Kim C, Ehling RA, Pankow A, et al
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Lancet Infect Dis. 2022 Mar 17. pii: S1473-3099(22)00129.
PubMed Abstract available

PARKER A, Dawood H
SARS-CoV-2 transmission: time to rethink public health strategy.
Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00137.
PubMed

COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
PubMed Abstract available

WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
PubMed Abstract available

ECKHARDT CM, O'Donnell MR
CD24Fc: an emerging COVID-19 therapy.
Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00125.
PubMed

PARKER EPK, Desai S, Marti M, O'Brien KL, et al
Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?
Lancet Infect Dis. 2022 Mar 9. pii: S1473-3099(22)00178.
PubMed

KRANTZ MS, Phillips EJ
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00123.
PubMed

ROSENBLUM HG, Gee J, Liu R, Marquez PL, et al
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00054.
PubMed Abstract available

DEAN AS, Tosas Auguet O, Glaziou P, Zignol M, et al
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.
Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(21)00808.
PubMed Abstract available

NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
PubMed

SASMONO RT, Santoso MS
Movement dynamics: reduced dengue cases during the COVID-19 pandemic.
Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00062.
PubMed

CHEN Y, Li N, Lourenco J, Wang L, et al
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study.
Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00025.
PubMed Abstract available

KIRBY T
Wolfgang Preiser-co-discoverer of SARS-CoV-2 variants.
Lancet Infect Dis. 2022;22:326.
PubMed

BURKI T
Education services in crisis due to COVID-19.
Lancet Infect Dis. 2022;22:321-322.
PubMed

SZEPESSY E, Arlett P, Sweeney F, Broich K, et al
COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
Lancet Infect Dis. 2022;22:315-316.
PubMed

DEPOORTERE E, Sowinski S, van Hengel A, Kerstiens B, et al
COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
Lancet Infect Dis. 2022;22:315.
PubMed

GUPTA S, Saarikko M, Pfutzner A, Raisanen IT, et al
Compromised periodontal status could increase mortality for patients with COVID-19.
Lancet Infect Dis. 2022;22:314.
PubMed

VILLAR JC, Gumisiriza N, Abreu LG, Maude RJ, et al
Defining post-COVID condition.
Lancet Infect Dis. 2022;22:316-317.
PubMed

SCHLAGENHAUF P, Deuel J
Concerts and COVID: can the beat go on?
Lancet Infect Dis. 2022;22:299-301.
PubMed

February 2022

COBELENS F, Suri RK, Helinski M, Makanga M, et al
Accelerating research and development of new vaccines against tuberculosis: a global roadmap.
Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(21)00810.
PubMed Abstract available

VANSHYLLA K, Tober-Lau P, Gruell H, Munn F, et al
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults.
Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(22)00135.
PubMed

ABEYWICKREMA M, Goodman AL
COVID-19 vaccine results might inform malaria vaccine strategies.
Lancet Infect Dis. 2022 Feb 24. pii: S1473-3099(22)00139.
PubMed

HART WS, Miller E, Andrews NJ, Waight P, et al
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis.
Lancet Infect Dis. 2022 Feb 14. pii: S1473-3099(22)00001.
PubMed Abstract available

YANG Y, Kenah E
Understanding how fast SARS-CoV-2 variants transmit from household studies.
Lancet Infect Dis. 2022 Feb 14. pii: S1473-3099(22)00053.
PubMed

THE LANCET INFECTIOUS DISEASES
Transitioning to endemicity with COVID-19 research.
Lancet Infect Dis. 2022 Feb 10. pii: S1473-3099(22)00070.
PubMed

DOWDY DW
Has the COVID-19 pandemic increased tuberculosis mortality?
Lancet Infect Dis. 2022;22:165-166.
PubMed

January 2022

MAHMUD-AL-RAFAT A, Hewins B, Mannan A, Kelvin DJ, et al
COVID-19 vaccine inequity, dependency, and production capability in low-income and middle-income countries: the case of Bangladesh.
Lancet Infect Dis. 2022 Jan 28. pii: S1473-3099(22)00028.
PubMed

CANDELLI M
COVID-19 vaccine: what are we doing and what should we do?
Lancet Infect Dis. 2022 Jan 27. pii: S1473-3099(22)00003.
PubMed

CORRAO G, Franchi M, Cereda D, Bortolan F, et al
Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.
Lancet Infect Dis. 2022 Jan 27. pii: S1473-3099(21)00813.
PubMed Abstract available

SRIDHAR S, Joaquin A, Bonaparte MI, Bueso A, et al
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00764.
PubMed Abstract available

BURKI T
The origin of SARS-CoV-2 variants of concern.
Lancet Infect Dis. 2022 Jan 13. pii: S1473-3099(22)00015.
PubMed

THE LANCET INFECTIOUS DISEASES
Time for Africa to future-proof, starting with COVID-19.
Lancet Infect Dis. 2022 Jan 13. pii: S1473-3099(22)00011.
PubMed

BURKI T
COVID-19 vaccine mandates in Europe.
Lancet Infect Dis. 2022;22:27-28.
PubMed

LLIBRE JM, Martin-Iguacel R, Revollo B
Practical measures for SARS-CoV-2 infection prevention - Authors' reply.
Lancet Infect Dis. 2022;22:21.
PubMed

FUJIKAWA T
Practical measures for SARS-CoV-2 infection prevention.
Lancet Infect Dis. 2022;22:20-21.
PubMed

CIRILLO N
Do health-care workers need a COVID-19 vaccine booster?
Lancet Infect Dis. 2022;22:20.
PubMed

ROMERO C, Diez JM, Gajardo R
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update.
Lancet Infect Dis. 2022;22:19.
PubMed

LALVANI A, Hakki S, Singanayagam A, Dunning J, et al
Transmissibility of SARS-CoV-2 among fully vaccinated individuals - Authors' reply.
Lancet Infect Dis. 2022;22:18-19.
PubMed

KO HHT
Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
Lancet Infect Dis. 2022;22:17-18.
PubMed

KNOL MJ, Backer JA, de Melker HE, van den Hof S, et al
Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
Lancet Infect Dis. 2022;22:16-17.
PubMed

FRANCO-PAREDES C
Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
Lancet Infect Dis. 2022;22:16.
PubMed

WU S, Archuleta S, Ming LS, Somani J, et al
Serial antigen rapid testing in staff of a large acute hospital.
Lancet Infect Dis. 2022;22:14-15.
PubMed

December 2021

SHAPIRO AE, Bender Ignacio RA
Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19.
Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00762.
PubMed

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00751.
PubMed Abstract available

LEWNARD JA, Mahmud A, Narayan T, Wahl B, et al
All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study.
Lancet Infect Dis. 2021 Dec 22. pii: S1473-3099(21)00746.
PubMed Abstract available

KUMAR A K A, Mishra N
Mortality during the COVID-19 pandemic: the blind spots in statistics.
Lancet Infect Dis. 2021 Dec 22. pii: S1473-3099(21)00767.
PubMed

GOOSSENS H, Derde L, Horby P, Bonten M, et al
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations.
Lancet Infect Dis. 2021 Dec 21. pii: S1473-3099(21)00705.
PubMed Abstract available

SORIANO JB, Murthy S, Marshall JC, Relan P, et al
A clinical case definition of post-COVID-19 condition by a Delphi consensus.
Lancet Infect Dis. 2021 Dec 21. pii: S1473-3099(21)00703.
PubMed Abstract available

KUMAR RAI G, Saluja T, Chaudhary S, Tamrakar D, et al
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Lancet Infect Dis. 2021 Dec 20. pii: S1473-3099(21)00455.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
Emerging SARS-CoV-2 variants: shooting the messenger.
Lancet Infect Dis. 2021 Dec 9. pii: S1473-3099(21)00770.
PubMed

CRODA J, Ranzani OT
Booster doses for inactivated COVID-19 vaccines: if, when, and for whom.
Lancet Infect Dis. 2021 Dec 7. pii: S1473-3099(21)00696.
PubMed

ZENG G, Wu Q, Pan H, Li M, et al
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Lancet Infect Dis. 2021 Dec 7. pii: S1473-3099(21)00681.
PubMed Abstract available

BAGCCHI S
Dismal global tuberculosis situation due to COVID-19.
Lancet Infect Dis. 2021;21:1636.
PubMed

PICKLES K, Copp T, Dodd RH, Cvejic E, et al
COVID-19 vaccine intentions in Australia.
Lancet Infect Dis. 2021;21:1627-1628.
PubMed

TROSEID M, Hites M, Barratt-Due A, Ader F, et al
Assessing the evidence on remdesivir.
Lancet Infect Dis. 2021;21:1630-1631.
PubMed

EDWARDS B, Biddle N, Gray M, Sollis K, et al
COVID-19 vaccine intentions in Australia.
Lancet Infect Dis. 2021;21:1628-1629.
PubMed

BAST E, Tang F, Dahn J, Palacio A, et al
Increased risk of hospitalisation and death with the delta variant in the USA.
Lancet Infect Dis. 2021;21:1629-1630.
PubMed

BURKI T
NHS Test and Trace's aims "overstated or not achieved".
Lancet Infect Dis. 2021;21:1637-1638.
PubMed

SAMARASEKERA U
Investigating the origins of novel pathogens.
Lancet Infect Dis. 2021;21:1633.
PubMed

THE LANCET INFECTIOUS DISEASES
Save our only planet.
Lancet Infect Dis. 2021;21:1613.
PubMed

ALVAREZ-MORENO C, Cassell JA, Donkor CM, Head MG, et al
Long-term consequences of the misuse of ivermectin data.
Lancet Infect Dis. 2021;21:1624-1626.
PubMed

The value of open-source clinical science in pandemic response: lessons from ISARIC.
Lancet Infect Dis. 2021;21:1623-1624.
PubMed

November 2021

DELAUGERRE C, Foissac F, Abdoul H, Masson G, et al
Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial.
Lancet Infect Dis. 2021 Nov 26. pii: S1473-3099(21)00673.
PubMed Abstract available

THIRUVENGADAM R, Awasthi A, Medigeshi G, Bhattacharya S, et al
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Lancet Infect Dis. 2021 Nov 25. pii: S1473-3099(21)00680.
PubMed Abstract available

WHEATLEY AK, Juno JA
COVID-19 vaccines in the age of the delta variant.
Lancet Infect Dis. 2021 Nov 25. pii: S1473-3099(21)00688.
PubMed

DESAI D, Khan AR, Soneja M, Mittal A, et al
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00674.
PubMed Abstract available

THIRUVENGADAM R, Binayke A, Awasthi A
SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines.
Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00697.
PubMed

KREMSNER PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, et al
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00677.
PubMed Abstract available

YADAV PD, Kumar S
Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy.
Lancet Infect Dis. 2021 Nov 23. pii: S1473-3099(21)00687.
PubMed

NASA P, Azoulay E, Chakrabarti A, Divatia JV, et al
Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method.
Lancet Infect Dis. 2021 Nov 10. pii: S1473-3099(21)00626.
PubMed Abstract available

KOJIMA N, Klausner JD
Protective immunity after recovery from SARS-CoV-2 infection.
Lancet Infect Dis. 2021 Nov 8. pii: S1473-3099(21)00676.
PubMed

MAGEE LA, von Dadelszen P, Kalafat E, Duncan EL, et al
COVID-19 vaccination in pregnancy-number needed to vaccinate to avoid harm.
Lancet Infect Dis. 2021 Nov 2. pii: S1473-3099(21)00691.
PubMed

GOMEZ ROMAN R, Tornieporth N, Cherian NG, Shurtleff AC, et al
Medical countermeasures against henipaviruses: a review and public health perspective.
Lancet Infect Dis. 2021 Nov 1. pii: S1473-3099(21)00400.
PubMed Abstract available

ARORA N, Gudipati A, Kundu R, Prabhakar N, et al
Post-COVID-19 mucormycosis presenting as chest wall cellulitis with mediastinitis.
Lancet Infect Dis. 2021;21:1611.
PubMed

BURKI T
Increasing COVID-19 vaccine uptake in Black Americans.
Lancet Infect Dis. 2021;21:1500-1501.
PubMed

WONG ICK, Wan EYF, Chui CSL, Li X, et al
Adverse event reporting and Bell's palsy risk after COVID-19 vaccination - Authors' reply.
Lancet Infect Dis. 2021;21:1492-1493.
PubMed

CHANG KC, Kong FY
Adverse event reporting and Bell's palsy risk after COVID-19 vaccination.
Lancet Infect Dis. 2021;21:1491-1492.
PubMed

KHOURI C, Roustit M, Cracowski JL
Adverse event reporting and Bell's palsy risk after COVID-19 vaccination.
Lancet Infect Dis. 2021;21:1490-1491.
PubMed

October 2021

WILDER-SMITH A
What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?
Lancet Infect Dis. 2021 Oct 29. pii: S1473-3099(21)00690.
PubMed

SINGANAYAGAM A, Hakki S, Dunning J, Madon KJ, et al
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
Lancet Infect Dis. 2021 Oct 29. pii: S1473-3099(21)00648.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
Unmet need for COVID-19 therapies in community settings.
Lancet Infect Dis. 2021 Oct 14. pii: S1473-3099(21)00633.
PubMed

SAH P, Moghadas SM, Vilches TN, Shoukat A, et al
Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas.
Lancet Infect Dis. 2021 Oct 7. pii: S1473-3099(21)00620.
PubMed

DEAL A, Halliday R, Crawshaw AF, Hayward SE, et al
Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review.
Lancet Infect Dis. 2021 Oct 6. pii: S1473-3099(21)00193.
PubMed Abstract available

BURKI T
Booster shots for COVID-19-the debate continues.
Lancet Infect Dis. 2021;21:1359-1360.
PubMed

KIRBY T
Van-Mai Cao-Lormeau-putting Pacific Islands on the map.
Lancet Infect Dis. 2021;21:1362.
PubMed

KENYON G
Australia's struggle with the delta variant.
Lancet Infect Dis. 2021;21:1358.
PubMed

BAGCCHI S
Infectious diseases in Afghanistan: a dismal scenario.
Lancet Infect Dis. 2021;21:1357.
PubMed

VACHARATHIT V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, et al
CoronaVac induces lower neutralising activity against variants of concern than natural infection.
Lancet Infect Dis. 2021;21:1352-1354.
PubMed

AUTZEN B, Dineen K, Vaughan D
Vaccinating children: fairness and childism.
Lancet Infect Dis. 2021;21:1354-1355.
PubMed

CHU CY, Marais G, Opperman C, Doolabh D, et al
Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa.
Lancet Infect Dis. 2021;21:1354.
PubMed

September 2021

SANDMANN FG, Jit M
Rapid COVID-19 vaccine rollout: immense success but challenges ahead.
Lancet Infect Dis. 2021 Sep 22. pii: S1473-3099(21)00616.
PubMed

HAAS EJ, McLaughlin JM, Khan F, Angulo FJ, et al
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Lancet Infect Dis. 2021 Sep 22. pii: S1473-3099(21)00566.
PubMed Abstract available

KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
Addendum needed on COVID-19 travel study - Authors' reply.
Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00562.
PubMed

ALTENBERG L
Addendum needed on COVID-19 travel study.
Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00454.
PubMed

XIA S, Zhang Y, Wang Y, Wang H, et al
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00462.
PubMed Abstract available

MOSTAGHIMI D, Valdez CN, Larson HT, Kalinich CC, et al
Prevention of host-to-host transmission by SARS-CoV-2 vaccines.
Lancet Infect Dis. 2021 Sep 14. pii: S1473-3099(21)00472.
PubMed Abstract available

ADER F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, et al
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Lancet Infect Dis. 2021 Sep 14. pii: S1473-3099(21)00485.
PubMed Abstract available

CHOUDHARY OP, Choudhary P, Singh I
India's COVID-19 vaccination drive: key challenges and resolutions.
Lancet Infect Dis. 2021 Sep 13. pii: S1473-3099(21)00567.
PubMed

LACERDA MVG, Bargieri DY
Protection against COVID-19: beyond antibodies.
Lancet Infect Dis. 2021 Sep 9. pii: S1473-3099(21)00561.
PubMed

SAURE D, O'Ryan M, Torres JP, Zuniga M, et al
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Lancet Infect Dis. 2021 Sep 9. pii: S1473-3099(21)00479.
PubMed Abstract available

JUTHANI PV, Gupta A, Borges KA, Price CC, et al
Hospitalisation among vaccine breakthrough COVID-19 infections.
Lancet Infect Dis. 2021 Sep 7. pii: S1473-3099(21)00558.
PubMed

BAGER P, Wohlfahrt J, Rasmussen M, Albertsen M, et al
Hospitalisation associated with SARS-CoV-2 delta variant in Denmark.
Lancet Infect Dis. 2021 Sep 3. pii: S1473-3099(21)00580.
PubMed

ANTONELLI M, Penfold RS, Merino J, Sudre CH, et al
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Lancet Infect Dis. 2021 Sep 1. pii: S1473-3099(21)00460.
PubMed Abstract available

BALAKRISHNAN VS
Memorialising Trump's pandemic (non-)response.
Lancet Infect Dis. 2021;21:1231.
PubMed

BAGCCHI S
Travel notice issued as Venezuela faces health system crisis.
Lancet Infect Dis. 2021;21:1219.
PubMed

DE AMBROGI M
Images of a world facing a pandemic.
Lancet Infect Dis. 2021;21:1225-1229.
PubMed

August 2021

TWOHIG KA, Nyberg T, Zaidi A, Thelwall S, et al
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(21)00475.
PubMed Abstract available

LECHIEN JR, Saussez S
Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants.
Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(21)00474.
PubMed

TEMPE DK
Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India?
Lancet Infect Dis. 2021 Aug 24. pii: S1473-3099(21)00450.
PubMed

BEAUTE J, Adlhoch C, Bundle N, Melidou A, et al
Testing indicators to monitor the COVID-19 pandemic.
Lancet Infect Dis. 2021 Aug 24. pii: S1473-3099(21)00461.
PubMed

UDWADIA Z, Balsari S, Ghafur A
Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? - Authors' reply.
Lancet Infect Dis. 2021 Aug 24. pii: S1473-3099(21)00480.
PubMed

CIRILLO N, Doan R
The association between COVID-19 vaccination and Bell's palsy.
Lancet Infect Dis. 2021 Aug 16. pii: S1473-3099(21)00467.
PubMed

WAN EYF, Chui CSL, Lai FTT, Chan EWY, et al
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
Lancet Infect Dis. 2021 Aug 16. pii: S1473-3099(21)00451.
PubMed Abstract available

MORAN E, Cook T, Goodman AL, Gupta RK, et al
Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials.
Lancet Infect Dis. 2021 Aug 16. pii: S1473-3099(21)00464.
PubMed

LI Y, Nair H
How reliable are COVID-19 burden estimates for India?
Lancet Infect Dis. 2021 Aug 13. pii: S1473-3099(21)00422.
PubMed

SNELL LB, Cliff PR, Charalampous T, Alcolea-Medina A, et al
Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants.
Lancet Infect Dis. 2021 Aug 13. pii: S1473-3099(21)00482.
PubMed

LAXMINARAYAN R, B CM, G VT, Arjun Kumar KV, et al
SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
Lancet Infect Dis. 2021 Aug 13. pii: S1473-3099(21)00393.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
COVID-19 vaccine equity and booster doses.
Lancet Infect Dis. 2021 Aug 12. pii: S1473-3099(21)00486.
PubMed

KADAMBARI S, Vanderslott S
Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK.
Lancet Infect Dis. 2021 Aug 9. pii: S1473-3099(21)00404.
PubMed

TODSEN T, Kirkby N, Benfield T
Is oropharyngeal sampling a reliable test to detect SARS-CoV-2?
Lancet Infect Dis. 2021 Aug 4. pii: S1473-3099(21)00395.
PubMed

TSANG NNY, So HC, Ip DKM
Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? - Authors' reply.
Lancet Infect Dis. 2021 Aug 4. pii: S1473-3099(21)00402.
PubMed

CHEN PZ, Koopmans M, Fisman DN, Gu FX, et al
Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic.
Lancet Infect Dis. 2021 Aug 2. pii: S1473-3099(21)00406.
PubMed

LONG CM, Marzi A
Biodefence research two decades on: worth the investment?
Lancet Infect Dis. 2021;21:e222-e233.
PubMed Abstract available

BALAKRISHNAN VS
Impact of COVID-19 on migrants and refugees.
Lancet Infect Dis. 2021;21:1076-1077.
PubMed

ESSO L, Epee E, Bilounga C, Abah A, et al
Cameroon's bold response to the COVID-19 pandemic during the first and second waves.
Lancet Infect Dis. 2021;21:1064-1065.
PubMed

LOTFINEJAD N, Peters A, Tartari E, Fankhauser-Rodriguez C, et al
Hand hygiene in health care: 20 years of ongoing advances and perspectives.
Lancet Infect Dis. 2021;21:e209-e221.
PubMed Abstract available

KIRBY T
Akiko Iwasaki-aiming at making vaccines better.
Lancet Infect Dis. 2021;21:1082.
PubMed

BURKE MJ, Del Rio C
Long COVID has exposed medicine's blind-spot.
Lancet Infect Dis. 2021;21:1062-1064.
PubMed

July 2021

TENBUSCH M, Schumacher S, Vogel E, Priller A, et al
Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.
Lancet Infect Dis. 2021 Jul 29. pii: S1473-3099(21)00420.
PubMed

WU S, Huang J, Zhang Z, Wu J, et al
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Lancet Infect Dis. 2021 Jul 26. pii: S1473-3099(21)00396.
PubMed Abstract available

MOJICA MF, Rossi MA, Vila AJ, Bonomo RA, et al
The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat.
Lancet Infect Dis. 2021 Jul 8. pii: S1473-3099(20)30868.
PubMed Abstract available

GLYNN JR, Dube A, Fielding K, Crampin AC, et al
The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.
Lancet Infect Dis. 2021 Jul 5. pii: S1473-3099(20)30994.
PubMed Abstract available

BURKI T
Global COVID-19 vaccine inequity.
Lancet Infect Dis. 2021;21:922-923.
PubMed

ADHIKARI B, Cheah PY
Vaccine hesitancy in the COVID-19 era.
Lancet Infect Dis. 2021 Jul 1. pii: S1473-3099(21)00390.
PubMed

LARKIN M
Mask confusion in NYC with abrupt CDC guidance changes.
Lancet Infect Dis. 2021;21:921.
PubMed

PANDEY A, Galvani AP
Role of the G20 in safe reopening of international travel.
Lancet Infect Dis. 2021;21:919.
PubMed

BAGCCHI S
Measles immunisation gaps in Africa.
Lancet Infect Dis. 2021;21:918.
PubMed

RANA S, Shah R, Ahmed S, Mothabbir G, et al
Post-disruption catch-up of child immunisation and health-care services in Bangladesh.
Lancet Infect Dis. 2021;21:913.
PubMed

June 2021

GILES B, Meredith P, Robson S, Smith G, et al
The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out.
Lancet Infect Dis. 2021 Jun 28. pii: S1473-3099(21)00356.
PubMed

ZOU X, Cao B
COVID-19 vaccines for children younger than 12 years: are we ready?
Lancet Infect Dis. 2021 Jun 28. pii: S1473-3099(21)00384.
PubMed

HAN B, Song Y, Li C, Yang W, et al
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Lancet Infect Dis. 2021 Jun 28. pii: S1473-3099(21)00319.
PubMed Abstract available

SHROTRI M, Krutikov M, Palmer T, Giddings R, et al
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Lancet Infect Dis. 2021 Jun 23. pii: S1473-3099(21)00289.
PubMed Abstract available

PRENDECKI M, Willicombe M
Single-dose SARS-CoV-2 vaccination efficacy in the elderly.
Lancet Infect Dis. 2021 Jun 23. pii: S1473-3099(21)00354.
PubMed

HYAMS C, Marlow R, Maseko Z, King J, et al
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
Lancet Infect Dis. 2021 Jun 23. pii: S1473-3099(21)00330.
PubMed Abstract available

CEVIK M, Mishra S
SARS-CoV-2 variants and considerations of inferring causality on disease severity.
Lancet Infect Dis. 2021 Jun 22. pii: S1473-3099(21)00338.
PubMed

PATONE M, Thomas K, Hatch R, Tan PS, et al
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study.
Lancet Infect Dis. 2021 Jun 22. pii: S1473-3099(21)00318.
PubMed Abstract available

BAGER P, Wohlfahrt J, Fonager J, Rasmussen M, et al
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study.
Lancet Infect Dis. 2021 Jun 22. pii: S1473-3099(21)00290.
PubMed Abstract available

JENA A
COVID-19 and SOS tweets in India.
Lancet Infect Dis. 2021 Jun 21. pii: S1473-3099(21)00355.
PubMed

THE LANCET INFECTIOUS DISEASES
Should we vaccinate children against SARS-CoV-2?
Lancet Infect Dis. 2021 Jun 10. pii: S1473-3099(21)00339.
PubMed

BALSARI S, Udwadia Z, Shaikh A, Ghafur A, et al
Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India.
Lancet Infect Dis. 2021 Jun 8. pii: S1473-3099(21)00329.
PubMed

OZONOFF A, Nanishi E, Levy O
Bell's palsy and SARS-CoV-2 vaccines-an unfolding story - Authors' reply.
Lancet Infect Dis. 2021 Jun 7. pii: S1473-3099(21)00323.
PubMed

CIRILLO N, Doan R
Bell's palsy and SARS-CoV-2 vaccines-an unfolding story.
Lancet Infect Dis. 2021 Jun 7. pii: S1473-3099(21)00273.
PubMed

MOGHADAS SM, Sah P, Vilches TN, Galvani AP, et al
Can the USA return to pre-COVID-19 normal by July 4?
Lancet Infect Dis. 2021 Jun 2. pii: S1473-3099(21)00324.
PubMed

BURKI T
HIV in the age of COVID-19.
Lancet Infect Dis. 2021;21:774-775.
PubMed

VASAN S, Pitisuttithum P
Vaccine development lessons between HIV and COVID-19.
Lancet Infect Dis. 2021;21:759-761.
PubMed

HOLT E
Russia's faltering vaccination programme.
Lancet Infect Dis. 2021;21:772.
PubMed

KONDRATIUK AL, Pillay TD, Kon OM, Lalvani A, et al
A conceptual framework to accelerate the clinical impact of evolving research into long COVID.
Lancet Infect Dis. 2021;21:756-757.
PubMed

May 2021

MANDENG N, Fai KN, Bebell LM, Boum Y, et al
Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong - Authors' reply.
Lancet Infect Dis. 2021 May 28. pii: S1473-3099(21)00288.
PubMed

LEKPA FK, Njonnou SRS, Balti E, Luma HN, et al
Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong.
Lancet Infect Dis. 2021 May 28. pii: S1473-3099(21)00271.
PubMed

CHEN Y, Shen H, Huang R, Tong X, et al
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
Lancet Infect Dis. 2021 May 27. pii: S1473-3099(21)00287.
PubMed

REVOLLO B, Blanco I, Soler P, Toro J, et al
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.
Lancet Infect Dis. 2021 May 27. pii: S1473-3099(21)00268.
PubMed Abstract available

PEELING RW, Heymann DL
Innovations in COVID-19 testing: the road from pandemic response to control.
Lancet Infect Dis. 2021 May 27. pii: S1473-3099(21)00291.
PubMed

HUSSAINI SMQ
A prescription for fair housing during the COVID-19 pandemic.
Lancet Infect Dis. 2021 May 25. pii: S1473-3099(21)00257.
PubMed

SIMON F, Watson H, Meynard JB, de Santi VP, et al
What chikungunya teaches us about COVID-19.
Lancet Infect Dis. 2021 May 19. pii: S1473-3099(21)00272.
PubMed

RAMANATHAN M, Ferguson ID, Miao W, Khavari PA, et al
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.
Lancet Infect Dis. 2021 May 19. pii: S1473-3099(21)00262.
PubMed

DAL-RE R, Bekker LG, Gluud C, Holm S, et al
Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
Lancet Infect Dis. 2021 May 18. pii: S1473-3099(21)00263.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
The rocky road to universal COVID-19 vaccination.
Lancet Infect Dis. 2021 May 14. pii: S1473-3099(21)00275.
PubMed

HUANG L, Cao B
Post-acute conditions of patients with COVID-19 not requiring hospital admission.
Lancet Infect Dis. 2021 May 10. pii: S1473-3099(21)00225.
PubMed

LUND LC, Hallas J, Nielsen H, Koch A, et al
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study.
Lancet Infect Dis. 2021 May 10. pii: S1473-3099(21)00211.
PubMed Abstract available

HAMILTON WL, Fieldman T, Jahun A, Warne B, et al
Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19.
Lancet Infect Dis. 2021 May 10. pii: S1473-3099(21)00251.
PubMed

PEELING RW, Olliaro P, Boeras D, Fongwen N, et al
SARS-CoV-2 rapid antigen detection tests - Authors' reply.
Lancet Infect Dis. 2021 May 4. pii: S1473-3099(21)00250.
PubMed

FOUZAS S
SARS-CoV-2 rapid antigen detection tests.
Lancet Infect Dis. 2021 May 4. pii: S1473-3099(21)00206.
PubMed

WEITZEL T, Perez C, Tapia D, Legarraga P, et al
SARS-CoV-2 rapid antigen detection tests.
Lancet Infect Dis. 2021 May 4. pii: S1473-3099(21)00249.
PubMed

SCHINDLER O, Steiner G, Trattner E, Schmon E, et al
Bilateral infiltrates in a health-care worker during the COVID-19 pandemic.
Lancet Infect Dis. 2021;21:742.
PubMed

NORTON A, Olliaro P, Sigfrid L, Carson G, et al
Long COVID: tackling a multifaceted condition requires a multidisciplinary approach.
Lancet Infect Dis. 2021;21:601-602.
PubMed

SCHWARTZ M
MIS-C: post-infectious syndrome or persistent infection?
Lancet Infect Dis. 2021;21:e116.
PubMed

MACKENZIE G
A year and a day of #Covid19uk tweets.
Lancet Infect Dis. 2021;21:616.
PubMed

BURKI T
Infectious diseases in Yemen.
Lancet Infect Dis. 2021;21:610-611.
PubMed

SAMARASEKERA U
CEPI prepares for future pandemics and epidemics.
Lancet Infect Dis. 2021;21:608.
PubMed

BARKSBY R
1st Women in Malaria conference.
Lancet Infect Dis. 2021;21:607.
PubMed

SIE A, Hanefeld J, Chaponda M, Chico RM, et al
Congenital malformations in sub-Saharan Africa-warnings of a silent epidemic?
Lancet Infect Dis. 2021;21:594-596.
PubMed

April 2021

DRURY RE, O'Connor D
Symptom study app provides real-world data on COVID-19 vaccines.
Lancet Infect Dis. 2021 Apr 27. pii: S1473-3099(21)00264.
PubMed

MENNI C, Klaser K, May A, Polidori L, et al
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Lancet Infect Dis. 2021 Apr 27. pii: S1473-3099(21)00224.
PubMed Abstract available

GILBERT SC, Lambe T
Recombinant protein vaccines against SARS-CoV-2.
Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00227.
PubMed

GOEPFERT PA, Fu B, Chabanon AL, Bonaparte MI, et al
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00147.
PubMed Abstract available

CHAPPELL KJ, Mordant FL, Li Z, Wijesundara DK, et al
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00200.
PubMed Abstract available

OBARO S
COVID-19 herd immunity by immunisation: are children in the herd?
Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00212.
PubMed

SPINELLI MA, Rutherford G, Gandhi M
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply.
Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00210.
PubMed

TRUNFIO M, Calcagno A, Bonora S, Di Perri G, et al
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases.
Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00205.
PubMed

THOMPSON RN, Hill EM, Gog JR
SARS-CoV-2 incidence and vaccine escape.
Lancet Infect Dis. 2021 Apr 13. pii: S1473-3099(21)00202.
PubMed

BOUM Y, Eyangoh S, Okomo MC
Beyond COVID-19-will self-sampling and testing become the norm?
Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00197.
PubMed

ONG SWX, Young BE, Lye DC
Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes.
Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00201.
PubMed

FRAMPTON D, Rampling T, Cross A, Bailey H, et al
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.
Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00170.
PubMed Abstract available

TSANG NNY, So HC, Ng KY, Cowling BJ, et al
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.
Lancet Infect Dis. 2021 Apr 12. pii: S1473-3099(21)00146.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
"In an ocean of ashes, islands of order": WHO's SARS-CoV-2 origin report.
Lancet Infect Dis. 2021 Apr 9. pii: S1473-3099(21)00213.
PubMed

HOLT E
COVID-19 vaccination in Ukraine.
Lancet Infect Dis. 2021;21:462.
PubMed

ADEPOJU P
Ebola and COVID-19 in DR Congo and Guinea.
Lancet Infect Dis. 2021;21:461.
PubMed

BURKI T
Behind Cuba's successful pandemic response.
Lancet Infect Dis. 2021;21:465-466.
PubMed

KENYON G
Vacuna-gate escalates in Peru.
Lancet Infect Dis. 2021;21:463.
PubMed

THE LANCET INFECTIOUS DISEASES
A glimmer of hope beyond the spring for Europe.
Lancet Infect Dis. 2021;21:439.
PubMed

JOMBART T
Why development of outbreak analytics tools should be valued, supported, and funded.
Lancet Infect Dis. 2021;21:458-459.
PubMed

March 2021

JENTSCH PC, Anand M, Bauch CT
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
Lancet Infect Dis. 2021 Mar 31. pii: S1473-3099(21)00057.
PubMed Abstract available

WELLS CR, Galvani AP
The interplay between COVID-19 restrictions and vaccination.
Lancet Infect Dis. 2021 Mar 31. pii: S1473-3099(21)00074.
PubMed

MAHARAJ AS, Parker J, Hopkins JP, Gournis E, et al
The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada.
Lancet Infect Dis. 2021 Mar 25. pii: S1473-3099(21)00151.
PubMed

BOUM Y, Fai KN, Nicolay B, Mboringong AB, et al
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study.
Lancet Infect Dis. 2021 Mar 25. pii: S1473-3099(21)00132.
PubMed Abstract available

PEELING RW, Olliaro P
Rolling out COVID-19 antigen rapid diagnostic tests: the time is now.
Lancet Infect Dis. 2021 Mar 25. pii: S1473-3099(21)00152.
PubMed

IVERSEN PL, Bavari S
Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?
Lancet Infect Dis. 2021 Mar 24. pii: S1473-3099(21)00149.
PubMed

YANG S, Li Y, Dai L, Wang J, et al
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Lancet Infect Dis. 2021 Mar 24. pii: S1473-3099(21)00127.
PubMed Abstract available

KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study.
Lancet Infect Dis. 2021 Mar 22. pii: S1473-3099(21)00134.
PubMed Abstract available

GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A, Hidalgo A, et al
Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks.
Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(20)30983.
PubMed Abstract available

MACINTYRE CR
Navigating post-vaccine COVID-19 futures in the health and economic context.
Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00126.
PubMed

CONTRERAS S, Priesemann V
Risking further COVID-19 waves despite vaccination.
Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00167.
PubMed

MOORE S, Hill EM, Tildesley MJ, Dyson L, et al
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00143.
PubMed Abstract available

SANDMANN FG, Davies NG, Vassall A, Edmunds WJ, et al
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(21)00079.
PubMed Abstract available

NICOLAS D, Coloma E, Pericas JM
Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19.
Lancet Infect Dis. 2021 Mar 9. pii: S1473-3099(21)00093.
PubMed

VAN GEMERT C, Tapo PS, Sero K
Border screening is an essential component of COVID-19 testing strategies in Vanuatu.
Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00135.
PubMed

ELLA R, Reddy S, Jogdand H, Sarangi V, et al
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00070.
PubMed Abstract available

LI JX, Zhu FC
Adjuvantation helps to optimise COVID-19 vaccine candidate.
Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00094.
PubMed

MEHTA P, Bunker CB, Ciurtin C, Porter JC, et al
Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy.
Lancet Infect Dis. 2021 Mar 8. pii: S1473-3099(21)00133.
PubMed

VAN DIJCK C, Tsoumanis A, Rotsaert A, Vuylsteke B, et al
Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
Lancet Infect Dis. 2021 Mar 4. pii: S1473-3099(20)30778.
PubMed Abstract available

BURKI T
COVID-19 among American Indians and Alaska Natives.
Lancet Infect Dis. 2021;21:325-326.
PubMed

SAMARASEKERA U
Feelings towards COVID-19 vaccination in Africa.
Lancet Infect Dis. 2021;21:324.
PubMed

BAGCCHI S
The world's largest COVID-19 vaccination campaign.
Lancet Infect Dis. 2021;21:323.
PubMed

PERMPALUNG N, Maertens J, Marr KA
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis.
Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(21)00060.
PubMed

JABEEN K, Farooqi J, Irfan M, Ali SA, et al
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis.
Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(21)00066.
PubMed

DROZD M, Pujades-Rodriguez M, Lillie PJ, Straw S, et al
Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.
Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(20)30978.
PubMed Abstract available

KOEHLER P, White PL, Verweij PE, Cornely OA, et al
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis - Authors' reply.
Lancet Infect Dis. 2021 Mar 1. pii: S1473-3099(21)00123.
PubMed

TARANTOLA A, Gautier L
Biostatistics to better detect fishy findings.
Lancet Infect Dis. 2021;21:316-317.
PubMed

February 2021

OZONOFF A, Nanishi E, Levy O
Bell's palsy and SARS-CoV-2 vaccines.
Lancet Infect Dis. 2021 Feb 24. pii: S1473-3099(21)00076.
PubMed

DARMON M, Dumas G
Anticipating outcomes for patients with COVID-19 and identifying prognosis patterns.
Lancet Infect Dis. 2021 Feb 23. pii: S1473-3099(21)00073.
PubMed

PEELING RW, Olliaro PL, Boeras DI, Fongwen N, et al
Scaling up COVID-19 rapid antigen tests: promises and challenges.
Lancet Infect Dis. 2021 Feb 23. pii: S1473-3099(21)00048.
PubMed Abstract available

GUTIERREZ-GUTIERREZ B, Del Toro MD, Borobia AM, Carcas A, et al
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study.
Lancet Infect Dis. 2021 Feb 23. pii: S1473-3099(21)00019.
PubMed Abstract available

SPINELLI MA, Glidden DV, Gennatas ED, Bielecki M, et al
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.
Lancet Infect Dis. 2021 Feb 22. pii: S1473-3099(20)30982.
PubMed Abstract available

OLLIARO P
What does 95% COVID-19 vaccine efficacy really mean?
Lancet Infect Dis. 2021 Feb 17. pii: S1473-3099(21)00075.
PubMed

ROMERO C, Diez JM, Gajardo R
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.
Lancet Infect Dis. 2021 Feb 16. pii: S1473-3099(21)00059.
PubMed

GHAFARI M, Kadivar A, Katzourakis A
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran.
Lancet Infect Dis. 2021 Feb 15. pii: S1473-3099(21)00053.
PubMed

NAZEMIPOUR M, Shakiba M, Mansournia MA
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran.
Lancet Infect Dis. 2021 Feb 15. pii: S1473-3099(21)00044.
PubMed

DARVISHIAN M, Sharafkhah M, Poustchi H, Malekzadeh R, et al
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran - Authors' reply.
Lancet Infect Dis. 2021 Feb 15. pii: S1473-3099(21)00058.
PubMed

INZAULE SC, Tessema SK, Kebede Y, Ogwell Ouma AE, et al
Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30939.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
The COVID-19 exit strategy-why we need to aim low.
Lancet Infect Dis. 2021 Feb 11. pii: S1473-3099(21)00080.
PubMed

ALAM I, Radovanovic A, Incitti R, Kamau AA, et al
CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants.
Lancet Infect Dis. 2021 Feb 8. pii: S1473-3099(21)00078.
PubMed

IVERSEN PL, Bavari S
Inactivated COVID-19 vaccines to make a global impact.
Lancet Infect Dis. 2021 Feb 3. pii: S1473-3099(21)00020.
PubMed

FAIRGRIEVE D, Holm S, Howells G, Kirchhelle C, et al
In favour of a bespoke COVID-19 vaccines compensation scheme.
Lancet Infect Dis. 2021 Feb 3. pii: S1473-3099(21)00065.
PubMed

WU Z, Hu Y, Xu M, Chen Z, et al
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Lancet Infect Dis. 2021 Feb 3. pii: S1473-3099(20)30987.
PubMed Abstract available

CORNELISSEN L, Andre E
Understanding the drivers of transmission of SARS-CoV-2.
Lancet Infect Dis. 2021 Feb 2. pii: S1473-3099(21)00005.
PubMed

MARKS M, Millat-Martinez P, Ouchi D, Roberts CH, et al
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.
Lancet Infect Dis. 2021 Feb 2. pii: S1473-3099(20)30985.
PubMed Abstract available

STRINGHINI S, Zaballa ME, Perez-Saez J, Pullen N, et al
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak.
Lancet Infect Dis. 2021 Feb 1. pii: S1473-3099(21)00054.
PubMed

BURKI T
The elusive elimination of river blindness.
Lancet Infect Dis. 2021;21:175-176.
PubMed

MAKONI M
New tuberculosis tests and drugs remain out of reach.
Lancet Infect Dis. 2021;21:174.
PubMed

THE LANCET INFECTIOUS DISEASES
An exceptional vaccination policy in exceptional circumstances.
Lancet Infect Dis. 2021;21:149.
PubMed

MANTHA S
Ratio, rate, or risk?
Lancet Infect Dis. 2021;21:165-166.
PubMed

BAUCH CT
Estimating the COVID-19 R number: a bargain with the devil?
Lancet Infect Dis. 2021;21:151-153.
PubMed

LI Y, Campbell H, Kulkarni D, Harpur A, et al
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries.
Lancet Infect Dis. 2021;21:193-202.
PubMed Abstract available

January 2021

MOHAPATRA PR, Mishra B
Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode.
Lancet Infect Dis. 2021 Jan 25. pii: S1473-3099(21)00045.
PubMed

ELLA R, Vadrevu KM, Jogdand H, Prasad S, et al
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Lancet Infect Dis. 2021 Jan 21. pii: S1473-3099(20)30942.
PubMed Abstract available

ROSTAD CA, Anderson EJ
Optimism and caution for an inactivated COVID-19 vaccine.
Lancet Infect Dis. 2021 Jan 21. pii: S1473-3099(20)30988.
PubMed

PALLETT SJC, Jones R, Randell P, Davies GW, et al
Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection.
Lancet Infect Dis. 2021 Jan 20. pii: S1473-3099(20)30990.
PubMed

GARDNER AR
COVID-19 through the Latinx infectious disease doctor's eyes.
Lancet Infect Dis. 2021 Jan 19. pii: S1473-3099(20)30885.
PubMed

LI F, Li YY, Liu MJ, Fang LQ, et al
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.
Lancet Infect Dis. 2021 Jan 18. pii: S1473-3099(20)30981.
PubMed Abstract available

MCMAHON DE, Gallman AE, Hruza GJ, Rosenbach M, et al
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration.
Lancet Infect Dis. 2021 Jan 15. pii: S1473-3099(20)30986.
PubMed

JARCHOW-MACDONALD AA, Burns R, Miller J, Kerr L, et al
Keeping childhood immunisation rates stable during the COVID-19 pandemic.
Lancet Infect Dis. 2021 Jan 15. pii: S1473-3099(20)30991.
PubMed

FIORENTINI S, Messali S, Zani A, Caccuri F, et al
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020.
Lancet Infect Dis. 2021 Jan 12. pii: S1473-3099(21)00007.
PubMed

ROTHE C
Multiple testing and the effect of NPIs on the spread of SARS-CoV-2.
Lancet Infect Dis. 2021 Jan 6. pii: S1473-3099(20)30935.
PubMed

BURKI T
Equitable distribution of COVID-19 vaccines.
Lancet Infect Dis. 2021;21:33-34.
PubMed

HOLT E
COVID-19 testing in Slovakia.
Lancet Infect Dis. 2021;21:32.
PubMed

THE LANCET INFECTIOUS DISEASES
Tuberculosis and malaria in the age of COVID-19.
Lancet Infect Dis. 2021;21:1.
PubMed

December 2020

DAVIES NG, Barnard RC, Jarvis CI, Russell TW, et al
Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study.
Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30984.
PubMed Abstract available

HENGEL B, Causer L, Matthews S, Smith K, et al
A decentralised point-of-care testing model to address inequities in the COVID-19 response.
Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30859.
PubMed Abstract available

SAMER C, Lacombe K, Calmy A
Cyber harassment of female scientists will not be the new norm.
Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30944.
PubMed

DUYSBURGH E, Mortgat L, Barbezange C, Dierick K, et al
Persistence of IgG response to SARS-CoV-2.
Lancet Infect Dis. 2020 Dec 17. pii: S1473-3099(20)30943.
PubMed

POUSTCHI H, Darvishian M, Mohammadi Z, Shayanrad A, et al
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30858.
PubMed Abstract available

DODD RH, Pickles K, Nickel B, Cvejic E, et al
Concerns and motivations about COVID-19 vaccination.
Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30926.
PubMed

KOEHLER P, Bassetti M, Chakrabarti A, Chen SCA, et al
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Lancet Infect Dis. 2020 Dec 14. pii: S1473-3099(20)30847.
PubMed Abstract available

ALLISON J, Badanjak S, Bach B, Bell C, et al
An interactive tracker for ceasefires in the time of COVID-19.
Lancet Infect Dis. 2020 Dec 14. pii: S1473-3099(20)30932.
PubMed

FLASCHE S, Edmunds WJ
The role of schools and school-aged children in SARS-CoV-2 transmission.
Lancet Infect Dis. 2020 Dec 8. pii: S1473-3099(20)30927.
PubMed

ISMAIL SA, Saliba V, Lopez Bernal J, Ramsay ME, et al
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England.
Lancet Infect Dis. 2020 Dec 8. pii: S1473-3099(20)30882.
PubMed Abstract available

SINGH JA, Upshur REG
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.
Lancet Infect Dis. 2020 Dec 8. pii: S1473-3099(20)30923.
PubMed Abstract available

MARSHALL JC, Murthy S, Diaz J
Fungal infections should be part of the core outcome set for COVID-19 - Authors' reply.
Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30681.
PubMed

VERWEIJ PE, Alanio A
Fungal infections should be part of the core outcome set for COVID-19.
Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30591.
PubMed

BROWN RCH, Savulescu J, Kelly D, Wilkinson D, et al
A public health ethic should inform policies on COVID-19 immunity passports - Authors' reply.
Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30922.
PubMed

BAYLIS F, Kofler N
A public health ethic should inform policies on COVID-19 immunity passports.
Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30918.
PubMed

MEYEROWITZ EA, Richterman A, Bogoch II, Low N, et al
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2.
Lancet Infect Dis. 2020 Dec 7. pii: S1473-3099(20)30837.
PubMed Abstract available

ARMITAGE R, Nellums LB
Antibiotic prescribing in general practice during COVID-19.
Lancet Infect Dis. 2020 Dec 1. pii: S1473-3099(20)30917.
PubMed

KAZI F, Mushtaq A
IDWeek 2020.
Lancet Infect Dis. 2020;20:1374.
PubMed

November 2020

YOUNG B, Tan TT, Leo YS
The place for remdesivir in COVID-19 treatment.
Lancet Infect Dis. 2020 Nov 26. pii: S1473-3099(20)30911.
PubMed

PRADO-VIVAR B, Becerra-Wong M, Guadalupe JJ, Marquez S, et al
A case of SARS-CoV-2 reinfection in Ecuador.
Lancet Infect Dis. 2020 Nov 23. pii: S1473-3099(20)30910.
PubMed

KOOPMANS M
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms.
Lancet Infect Dis. 2020 Nov 20. pii: S1473-3099(20)30912.
PubMed

KAMPF G, Lemmen S, Suchomel M
Ct values and infectivity of SARS-CoV-2 on surfaces.
Lancet Infect Dis. 2020 Nov 19. pii: S1473-3099(20)30883.
PubMed

ROARTY C, Tonry C, McFetridge L, Mitchell H, et al
Kinetics and seroprevalence of SARS-CoV-2 antibodies in children.
Lancet Infect Dis. 2020 Nov 19. pii: S1473-3099(20)30884.
PubMed

BAR-ZEEV N, Kochhar S
Expecting the unexpected with COVID-19 vaccines.
Lancet Infect Dis. 2020 Nov 17. pii: S1473-3099(20)30870.
PubMed

ZHANG Y, Zeng G, Pan H, Li C, et al
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Lancet Infect Dis. 2020 Nov 17. pii: S1473-3099(20)30843.
PubMed Abstract available

PEIFFER-SMADJA N, Rebeaud ME, Guihur A, Mahamat-Saleh Y, et al
Hydroxychloroquine and COVID-19: a tale of populism and obscurantism.
Lancet Infect Dis. 2020 Nov 13. pii: S1473-3099(20)30866.
PubMed

NG OT, Marimuthu K, Koh V, Pang J, et al
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
Lancet Infect Dis. 2020 Nov 2. pii: S1473-3099(20)30833.
PubMed Abstract available

BADR HS, Gardner LM
Limitations of using mobile phone data to model COVID-19 transmission in the USA.
Lancet Infect Dis. 2020 Nov 2. pii: S1473-3099(20)30861.
PubMed

KIRBY T
Matshidiso Moeti, first female WHO Regional Director.
Lancet Infect Dis. 2020;20:1244.
PubMed

MUSHTAQ A, Kazi F
New guidelines to treat bacterial infections.
Lancet Infect Dis. 2020;20:1239.
PubMed

JESUDASON T
The 11th annual NTD NGO Network conference.
Lancet Infect Dis. 2020;20:1238.
PubMed

October 2020

IVERSEN K, Bundgaard H, Harritshoj L, Ullum H, et al
Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies - Authors' reply.
Lancet Infect Dis. 2020 Oct 30. pii: S1473-3099(20)30849.
PubMed

CHOY KW
Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies.
Lancet Infect Dis. 2020 Oct 30. pii: S1473-3099(20)30787.
PubMed

VAN ELSLANDE J, Andre E, Van Ranst M, Lagrou K, et al
Immunoassays for anti-SARS-CoV-2 antibodies: recent insights.
Lancet Infect Dis. 2020 Oct 30. pii: S1473-3099(20)30846.
PubMed

HODGSON SH, Mansatta K, Mallett G, Harris V, et al
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
Lancet Infect Dis. 2020 Oct 27. pii: S1473-3099(20)30773.
PubMed Abstract available

YANG W, Kandula S, Huynh M, Greene SK, et al
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
Lancet Infect Dis. 2020 Oct 19. pii: S1473-3099(20)30769.
PubMed Abstract available

BROWN RCH, Kelly D, Wilkinson D, Savulescu J, et al
The scientific and ethical feasibility of immunity passports.
Lancet Infect Dis. 2020 Oct 16. pii: S1473-3099(20)30766.
PubMed Abstract available

ISAKOVA-SIVAK I, Rudenko L
A promising inactivated whole-virion SARS-CoV-2 vaccine.
Lancet Infect Dis. 2020 Oct 15. pii: S1473-3099(20)30832.
PubMed

XIA S, Zhang Y, Wang Y, Wang H, et al
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Lancet Infect Dis. 2020 Oct 15. pii: S1473-3099(20)30831.
PubMed Abstract available

TILLETT RL, Sevinsky JR, Hartley PD, Kerwin H, et al
Genomic evidence for reinfection with SARS-CoV-2: a case study.
Lancet Infect Dis. 2020 Oct 12. pii: S1473-3099(20)30764.
PubMed Abstract available

IWASAKI A
What reinfections mean for COVID-19.
Lancet Infect Dis. 2020 Oct 12. pii: S1473-3099(20)30783.
PubMed

VEHRESCHILD MJGT, Tacconelli E, Giske CG, Peschel A, et al
Beyond COVID-19-a paradigm shift in infection management?
Lancet Infect Dis. 2020 Oct 9. pii: S1473-3099(20)30789.
PubMed

THE LANCET INFECTIOUS DISEASES
The intersection of COVID-19 and mental health.
Lancet Infect Dis. 2020 Oct 8. pii: S1473-3099(20)30797.
PubMed

BURKI T
China's successful control of COVID-19.
Lancet Infect Dis. 2020 Oct 8. pii: S1473-3099(20)30800.
PubMed

PERLMAN S, Zumla A
MERS-CoV in Africa-an enigma with relevance to COVID-19.
Lancet Infect Dis. 2020 Oct 6. pii: S1473-3099(20)30578.
PubMed

MOK CKP, Zhu A, Zhao J, Lau EHY, et al
T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study.
Lancet Infect Dis. 2020 Oct 6. pii: S1473-3099(20)30599.
PubMed Abstract available

KHALIL A, von Dadelszen P, Kalafat E, Sebghati M, et al
Change in obstetric attendance and activities during the COVID-19 pandemic.
Lancet Infect Dis. 2020 Oct 5. pii: S1473-3099(20)30779.
PubMed

GALVAO J
COVID-19: the deadly threat of misinformation.
Lancet Infect Dis. 2020 Oct 5. pii: S1473-3099(20)30721.
PubMed

BURKI T
COVID-19 claims another victim.
Lancet Infect Dis. 2020;20:1129-1130.
PubMed

MAKONI M
COVID-19 in Africa: half a year later.
Lancet Infect Dis. 2020;20:1127.
PubMed

RATHI S, Ish P, Kalantri A, Kalantri S, et al
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
Lancet Infect Dis. 2020;20:1118-1119.
PubMed

PRINCIPI N, Esposito S
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Lancet Infect Dis. 2020;20:1118.
PubMed

KIRBY T
Evelina Tacconelli-two viruses, two wars.
Lancet Infect Dis. 2020;20:1132.
PubMed

BALAKRISHNAN VS
The arrival of Sputnik V.
Lancet Infect Dis. 2020;20:1128.
PubMed

September 2020

FRANCO-PAREDES C, Ghandnoosh N, Latif H, Krsak M, et al
Decarceration and community re-entry in the COVID-19 era.
Lancet Infect Dis. 2020 Sep 29. pii: S1473-3099(20)30730.
PubMed Abstract available

MONDELLI MU, Colaneri M, Seminari EM, Baldanti F, et al
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions.
Lancet Infect Dis. 2020 Sep 29. pii: S1473-3099(20)30678.
PubMed

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.
Lancet Infect Dis. 2020 Sep 23. pii: S1473-3099(20)30634.
PubMed Abstract available

HOULIHAN CF, Beale R
The complexities of SARS-CoV-2 serology.
Lancet Infect Dis. 2020 Sep 23. pii: S1473-3099(20)30699.
PubMed

TEBOH-EWUNGKEM MI, Ngwa GA
COVID-19 in malaria-endemic regions: potential consequences for malaria intervention coverage, morbidity, and mortality.
Lancet Infect Dis. 2020 Sep 21. pii: S1473-3099(20)30763.
PubMed

WEISS DJ, Bertozzi-Villa A, Rumisha SF, Amratia P, et al
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis.
Lancet Infect Dis. 2020 Sep 21. pii: S1473-3099(20)30700.
PubMed Abstract available

GATALO O, Tseng K, Hamilton A, Lin G, et al
Associations between phone mobility data and COVID-19 cases.
Lancet Infect Dis. 2020 Sep 15. pii: S1473-3099(20)30725.
PubMed

RHODES A, Hoq M, Measey MA, Danchin M, et al
Intention to vaccinate against COVID-19 in Australia.
Lancet Infect Dis. 2020 Sep 14. pii: S1473-3099(20)30724.
PubMed

BAX A, Bax CE, Stadnytskyi V, Anfinrud P, et al
SARS-CoV-2 transmission via speech-generated respiratory droplets.
Lancet Infect Dis. 2020 Sep 11. pii: S1473-3099(20)30726.
PubMed

THE LANCET INFECTIOUS DISEASES
Curing COVID-19.
Lancet Infect Dis. 2020 Sep 10. pii: S1473-3099(20)30706.
PubMed

THE LANCET INFECTIOUS DISEASES
Air travel in the time of COVID-19.
Lancet Infect Dis. 2020;20:993.
PubMed

BURKI T
The origin of SARS-CoV-2.
Lancet Infect Dis. 2020;20:1018-1019.
PubMed

YELIN D, Wirtheim E, Vetter P, Kalil AC, et al
Long-term consequences of COVID-19: research needs.
Lancet Infect Dis. 2020 Sep 1. pii: S1473-3099(20)30701.
PubMed

August 2020

GRASSLY NC, Pons-Salort M, Parker EPK, White PJ, et al
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study.
Lancet Infect Dis. 2020 Aug 18. pii: S1473-3099(20)30630.
PubMed Abstract available

JIANG L, Tang K, Levin M, Irfan O, et al
COVID-19 and multisystem inflammatory syndrome in children and adolescents.
Lancet Infect Dis. 2020 Aug 17. pii: S1473-3099(20)30651.
PubMed Abstract available

JAVELLE E, Raoult D
COVID-19 pandemic more than a century after the Spanish flu.
Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30650.
PubMed

HEATH PT, Le Doare K, Khalil A
Inclusion of pregnant women in COVID-19 vaccine development.
Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30638.
PubMed

MANHEIM D
Evolving ethics of COVID-19 challenge trials.
Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30649.
PubMed

STANDL F, Jockel KH, Brune B, Schmidt B, et al
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
Lancet Infect Dis. 2020 Aug 11. pii: S1473-3099(20)30648.
PubMed

GARDNER L, Ratcliff J, Dong E, Katz A, et al
A need for open public data standards and sharing in light of COVID-19.
Lancet Infect Dis. 2020 Aug 10. pii: S1473-3099(20)30635.
PubMed

EPSTEIN JB, Chow K, Mathias R
Dental procedure aerosols and COVID-19.
Lancet Infect Dis. 2020 Aug 10. pii: S1473-3099(20)30636.
PubMed

KALK A, Schultz A
SARS-CoV-2 epidemic in African countries-are we losing perspective?
Lancet Infect Dis. 2020 Aug 7. pii: S1473-3099(20)30563.
PubMed

HEYWOOD AE, Macintyre CR
Elimination of COVID-19: what would it look like and is it possible?
Lancet Infect Dis. 2020 Aug 6. pii: S1473-3099(20)30633.
PubMed

ARORA RK, Joseph A, Van Wyk J, Rocco S, et al
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard.
Lancet Infect Dis. 2020 Aug 4. pii: S1473-3099(20)30631.
PubMed

JOY M, Hobbs FDR, McGagh D, Akinyemi O, et al
Excess mortality from COVID-19 in an English sentinel network population.
Lancet Infect Dis. 2020 Aug 4. pii: S1473-3099(20)30632.
PubMed

IVERSEN K, Bundgaard H, Hasselbalch RB, Kristensen JH, et al
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study.
Lancet Infect Dis. 2020 Aug 3. pii: S1473-3099(20)30589.
PubMed Abstract available

KUCHARSKI AJ, Nilles EJ
Using serological data to understand unobserved SARS-CoV-2 risk in health-care settings.
Lancet Infect Dis. 2020 Aug 3. pii: S1473-3099(20)30579.
PubMed

BURKI T
The indirect impact of COVID-19 on women.
Lancet Infect Dis. 2020;20:904-905.
PubMed

JESUDASON T
New WHO road map for NTD recovery post COVID-19.
Lancet Infect Dis. 2020;20:902.
PubMed

KIRBY T
Annelies Wilder-Smith.
Lancet Infect Dis. 2020;20:907.
PubMed

BARBER S
Death by racism.
Lancet Infect Dis. 2020;20:903.
PubMed

July 2020

DAWOOD FS, Ricks P, Njie GJ, Daugherty M, et al
Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis.
Lancet Infect Dis. 2020 Jul 29. pii: S1473-3099(20)30581.
PubMed Abstract available

GRILLO F, Barisione E, Ball L, Mastracci L, et al
Lung fibrosis: an undervalued finding in COVID-19 pathological series.
Lancet Infect Dis. 2020 Jul 28. pii: S1473-3099(20)30582.
PubMed

PEELING RW, Boeras D, Wilder-Smith A, Sall A, et al
Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential.
Lancet Infect Dis. 2020 Jul 24. pii: S1473-3099(20)30461.
PubMed Abstract available

BIELICKI JA, Duval X, Gobat N, Goossens H, et al
Monitoring approaches for health-care workers during the COVID-19 pandemic.
Lancet Infect Dis. 2020 Jul 23. pii: S1473-3099(20)30458.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
The COVID-19 infodemic.
Lancet Infect Dis. 2020 Jul 17. pii: S1473-3099(20)30565.
PubMed

COOK M
Potential factors linked to high COVID-19 death rates in British minority ethnic groups.
Lancet Infect Dis. 2020 Jul 17. pii: S1473-3099(20)30583.
PubMed

PEELING RW, Wedderburn CJ, Garcia PJ, Boeras D, et al
Serology testing in the COVID-19 pandemic response.
Lancet Infect Dis. 2020 Jul 17. pii: S1473-3099(20)30517.
PubMed Abstract available

EBERHARDT JN, Breuckmann NP, Eberhardt CS
Challenges and issues of SARS-CoV-2 pool testing.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30467.
PubMed

BEHRMANN O, Spiegel M
COVID-19: from rapid genome sequencing to fast decisions.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30580.
PubMed

LOHSE S, Pfuhl T, Berko-Gottel B, Gartner B, et al
Challenges and issues of SARS-CoV-2 pool testing - Authors' reply.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30455.
PubMed

PEREZ-SAEZ J, Lauer SA, Kaiser L, Regard S, et al
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30584.
PubMed

MISHRA B, Behera B, Mohanty M, Ravindra A, et al
Challenges and issues of SARS-CoV-2 pool testing.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30463.
PubMed

MEREDITH LW, Hamilton WL, Warne B, Houldcroft CJ, et al
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30562.
PubMed Abstract available

LEE J, Kim SY, Sung H, Lee SW, et al
Challenges and issues of SARS-CoV-2 pool testing.
Lancet Infect Dis. 2020 Jul 14. pii: S1473-3099(20)30516.
PubMed

MEI Q, Li J, Du R, Yuan X, et al
Assessment of patients who tested positive for COVID-19 after recovery.
Lancet Infect Dis. 2020 Jul 6. pii: S1473-3099(20)30433.
PubMed

GOLDMAN E
Exaggerated risk of transmission of COVID-19 by fomites.
Lancet Infect Dis. 2020 Jul 3. pii: S1473-3099(20)30561.
PubMed

HOXHA A, Wyndham-Thomas C, Klamer S, Dubourg D, et al
Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities.
Lancet Infect Dis. 2020 Jul 3. pii: S1473-3099(20)30560.
PubMed

PETERSEN E, Koopmans M, Go U, Hamer DH, et al
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
Lancet Infect Dis. 2020 Jul 3. pii: S1473-3099(20)30484.
PubMed Abstract available

SIKKEMA RS, Pas SD, Nieuwenhuijse DF, O'Toole A, et al
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study.
Lancet Infect Dis. 2020 Jul 2. pii: S1473-3099(20)30527.
PubMed Abstract available

BALAKRISHNAN VS
COVID-19: Playing away the pandemic.
Lancet Infect Dis. 2020;20:792.
PubMed

VENKATESAN P
COVID-19 in Iran: round 2.
Lancet Infect Dis. 2020;20:784.
PubMed

TRIUNFOL M
High COVID-19 testing rate in Portugal.
Lancet Infect Dis. 2020;20:783.
PubMed

BAGCCHI S
Stigma during the COVID-19 pandemic.
Lancet Infect Dis. 2020;20:782.
PubMed

BADR HS, Du H, Marshall M, Dong E, et al
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study.
Lancet Infect Dis. 2020 Jul 1. pii: S1473-3099(20)30553.
PubMed Abstract available

AZMAN AS, Luquero FJ
From China: hope and lessons for COVID-19 control.
Lancet Infect Dis. 2020;20:756-757.
PubMed

ZHANG J, Litvinova M, Wang W, Wang Y, et al
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.
Lancet Infect Dis. 2020;20:793-802.
PubMed Abstract available

JIA Z, Lu Z
Modelling COVID-19 transmission: from data to intervention.
Lancet Infect Dis. 2020;20:757-758.
PubMed

NIEHUS R, De Salazar PM, Taylor AR, Lipsitch M, et al
Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China.
Lancet Infect Dis. 2020;20:803-808.
PubMed Abstract available

AHMED H, Allaf M, Elghazaly H
COVID-19 and medical education.
Lancet Infect Dis. 2020;20:777-778.
PubMed

BAUD D, Nielsen-Saines K, Qi X, Musso D, et al
Authors' reply.
Lancet Infect Dis. 2020;20:775-776.
PubMed

BURKI T
Global shortage of personal protective equipment.
Lancet Infect Dis. 2020;20:785-786.
PubMed

Global outbreak research: harmony not hegemony.
Lancet Infect Dis. 2020;20:770-772.
PubMed

June 2020

DODD RH, Cvejic E, Bonner C, Pickles K, et al
Willingness to vaccinate against COVID-19 in Australia.
Lancet Infect Dis. 2020 Jun 30. pii: S1473-3099(20)30559.
PubMed

ABBAS M, Pittet D
Surfing the COVID-19 scientific wave.
Lancet Infect Dis. 2020 Jun 30. pii: S1473-3099(20)30558.
PubMed

SARDANELLI F, Cozzi A, Monfardini L, Bna C, et al
Association of mediastinal lymphadenopathy with COVID-19 prognosis.
Lancet Infect Dis. 2020 Jun 19. pii: S1473-3099(20)30521.
PubMed

HUBICHE T, Le Duff F, Chiaverini C, Giordanengo V, et al
Negative SARS-CoV-2 PCR in patients with chilblain-like lesions.
Lancet Infect Dis. 2020 Jun 18. pii: S1473-3099(20)30518.
PubMed

PITZER VE, Cohen T
Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2.
Lancet Infect Dis. 2020 Jun 17. pii: S1473-3099(20)30514.
PubMed

JING QL, Liu MJ, Zhang ZB, Fang LQ, et al
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
Lancet Infect Dis. 2020 Jun 17. pii: S1473-3099(20)30471.
PubMed Abstract available

AFRA TP, T MR, Bishnoi A, Hafi NB, et al
Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
Lancet Infect Dis. 2020 Jun 16. pii: S1473-3099(20)30472.
PubMed

MACINTYRE CR
Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices.
Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30512.
PubMed

KUCHARSKI AJ, Klepac P, Conlan AJK, Kissler SM, et al
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.
Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30457.
PubMed Abstract available

TEDDER RS, Semple MG
Appropriate selection of convalescent plasma donors for COVID-19.
Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30470.
PubMed

NTOUMI F, Velavan TP
COVID-19 in Africa: between hope and reality.
Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30465.
PubMed

COX RJ, Brokstad KA, Krammer F, Langeland N, et al
Seroconversion in household members of COVID-19 outpatients.
Lancet Infect Dis. 2020 Jun 15. pii: S1473-3099(20)30466.
PubMed

A minimal common outcome measure set for COVID-19 clinical research.
Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30483.
PubMed Abstract available

OOI EE, Low JG
Asymptomatic SARS-CoV-2 infection.
Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30460.
PubMed

TABATA S, Imai K, Kawano S, Ikeda M, et al
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis.
Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30482.
PubMed Abstract available

HUNG IF, Cheng VC, Li X, Tam AR, et al
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.
Lancet Infect Dis. 2020 Jun 12. pii: S1473-3099(20)30364.
PubMed Abstract available

THE LANCET INFECTIOUS DISEASES
Political casualties of the COVID-19 pandemic.
Lancet Infect Dis. 2020 Jun 11. pii: S1473-3099(20)30496.
PubMed

CARSANA L, Sonzogni A, Nasr A, Rossi RS, et al
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.
Lancet Infect Dis. 2020 Jun 8. pii: S1473-3099(20)30434.
PubMed Abstract available

YI ES, Cecchini MJ, Bois MC
Pathologists in pursuit of the COVID-19 culprit.
Lancet Infect Dis. 2020 Jun 8. pii: S1473-3099(20)30449.
PubMed

MCDONALD ES
COVID-19 and essential pregnant worker policies.
Lancet Infect Dis. 2020 Jun 2. pii: S1473-3099(20)30446.
PubMed

EKTORP E
Death threats after a trial on chloroquine for COVID-19.
Lancet Infect Dis. 2020;20:661.
PubMed

NAKKAZI E
Obstacles to COVID-19 control in east Africa.
Lancet Infect Dis. 2020;20:660.
PubMed

HOLT E
COVID-19 lockdown of Roma settlements in Slovakia.
Lancet Infect Dis. 2020;20:659.
PubMed

KOO JR, Cook AR, Park M, Sun Y, et al
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study.
Lancet Infect Dis. 2020;20:678-688.
PubMed Abstract available

MOUSAVI SH, Shah J, Giang HTN, Al-Ahdal TMA, et al
The first COVID-19 case in Afghanistan acquired from Iran.
Lancet Infect Dis. 2020;20:657-658.
PubMed

LEWNARD JA, Lo NC
Scientific and ethical basis for social-distancing interventions against COVID-19.
Lancet Infect Dis. 2020;20:631-633.
PubMed

KELVIN AA, Halperin S
COVID-19 in children: the link in the transmission chain.
Lancet Infect Dis. 2020;20:633-634.
PubMed

RUAN S
Likelihood of survival of coronavirus disease 2019.
Lancet Infect Dis. 2020;20:630-631.
PubMed

THE LANCET INFECTIOUS DISEASES
Riding the coronacoaster of uncertainty.
Lancet Infect Dis. 2020;20:629.
PubMed

HUSSAINI SMQ
Dearth of infectious diseases physicians as the USA faces a global pandemic.
Lancet Infect Dis. 2020;20:648-649.
PubMed

May 2020

JAMROZIK E, Selgelid MJ
COVID-19 human challenge studies: ethical issues.
Lancet Infect Dis. 2020 May 29. pii: S1473-3099(20)30438.
PubMed Abstract available

OSORIO NS, Correia-Neves M
Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays.
Lancet Infect Dis. 2020 May 28. pii: S1473-3099(20)30435.
PubMed

WOOD SN, Wit EC, Fasiolo M, Green PJ, et al
COVID-19 and the difficulty of inferring epidemiological parameters from clinical data.
Lancet Infect Dis. 2020 May 28. pii: S1473-3099(20)30437.
PubMed

VERITY R, Okell L, Dorigatti I, Winskill P, et al
COVID-19 and the difficulty of inferring epidemiological parameters from clinical data - Authors' reply.
Lancet Infect Dis. 2020 May 28. pii: S1473-3099(20)30443.
PubMed

TILANGI P, Desai D, Khan A, Soneja M, et al
Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
Lancet Infect Dis. 2020 May 22. pii: S1473-3099(20)30430.
PubMed

A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation.
Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30426.
PubMed

BAUCH CT, Anand M
COVID-19: when should quarantine be enforced?
Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30428.
PubMed

PEAK CM, Kahn R, Grad YH, Childs LM, et al
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study.
Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30361.
PubMed Abstract available

HAN MS, Byun JH, Cho Y, Rim JH, et al
RT-PCR for SARS-CoV-2: quantitative versus qualitative.
Lancet Infect Dis. 2020 May 20. pii: S1473-3099(20)30424.
PubMed

MEMISH ZA, Aljerian N, Ebrahim SH
Tale of three seeding patterns of SARS-CoV-2 in Saudi Arabia.
Lancet Infect Dis. 2020 May 19. pii: S1473-3099(20)30425.
PubMed

KHALIL A, Hill R, Ladhani S, Pattisson K, et al
COVID-19 screening of health-care workers in a London maternity hospital.
Lancet Infect Dis. 2020 May 18. pii: S1473-3099(20)30403.
PubMed

GUARNERI C, Rullo EV, Pavone P, Berretta M, et al
Silent COVID-19: what your skin can reveal.
Lancet Infect Dis. 2020 May 18. pii: S1473-3099(20)30402.
PubMed

BUONSENSO D, Parri N, De Rose C, Valentini P, et al
Toward a clinically based classification of disease severity for paediatric COVID-19.
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30396.
PubMed

DE LUSIGNAN S, Dorward J, Correa A, Jones N, et al
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study.
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30371.
PubMed Abstract available

BOHMER MM, Buchholz U, Corman VM, Hoch M, et al
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series.
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30314.
PubMed Abstract available

CHEN D, Tang F, Lu S, Song Q, et al
Toward a clinically based classification of disease severity for paediatric COVID-19 - Authors' reply.
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30397.
PubMed

SIMPSON CR, Thomas BD, Challen K, De Angelis D, et al
The UK hibernated pandemic influenza research portfolio: triggered for COVID-19.
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30398.
PubMed

RYBNIKER J, Fatkenheuer G
Importance of precise data on SARS-CoV-2 transmission dynamics control.
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30359.
PubMed

JORDAN RE, Adab P
Who is most likely to be infected with SARS-CoV-2?
Lancet Infect Dis. 2020 May 15. pii: S1473-3099(20)30395.
PubMed

WRIGHT DJM
Prevention of the cytokine storm in COVID-19.
Lancet Infect Dis. 2020 May 7. pii: S1473-3099(20)30376.
PubMed

LIPSITCH M, Perlman S, Waldor MK
Testing COVID-19 therapies to prevent progression of mild disease.
Lancet Infect Dis. 2020 May 6. pii: S1473-3099(20)30372.
PubMed

WELLS CR, Stearns JK, Lutumba P, Galvani AP, et al
COVID-19 on the African continent.
Lancet Infect Dis. 2020 May 6. pii: S1473-3099(20)30374.
PubMed

MBOPI-KEOU FX, Pondi JE, Sosso MA
COVID-19 in Cameroon: a crucial equation to resolve.
Lancet Infect Dis. 2020 May 6. pii: S1473-3099(20)30373.
PubMed

CHETTERJE P
Gaps in India's preparedness for COVID-19 control.
Lancet Infect Dis. 2020;20:544.
PubMed

RANSCOMBE P
Rural areas at risk during COVID-19 pandemic.
Lancet Infect Dis. 2020;20:545.
PubMed

THE LANCET INFECTIOUS DISEASES
COVID-19: endgames.
Lancet Infect Dis. 2020;20:511.
PubMed

BURKI T
COVID-19 in Latin America.
Lancet Infect Dis. 2020;20:547-548.
PubMed

TO KK, Tsang OT, Leung WS, Tam AR, et al
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
Lancet Infect Dis. 2020;20:565-574.
PubMed Abstract available

CHEN Y, Li L
SARS-CoV-2: virus dynamics and host response.
Lancet Infect Dis. 2020;20:515-516.
PubMed

MCBRYDE E
The value of early transmission dynamic studies in emerging infectious diseases.
Lancet Infect Dis. 2020;20:512-513.
PubMed

SIMPSON S, Kaufmann MC, Glozman V, Chakrabarti A, et al
Disease X: accelerating the development of medical countermeasures for the next pandemic.
Lancet Infect Dis. 2020;20:e108-e115.
PubMed Abstract available

April 2020

LANG M, Som A, Mendoza DP, Flores EJ, et al
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT.
Lancet Infect Dis. 2020 Apr 30. pii: S1473-3099(20)30367.
PubMed

ENDEMAN H, van der Zee P, van Genderen ME, van den Akker JPC, et al
Progressive respiratory failure in COVID-19: a hypothesis.
Lancet Infect Dis. 2020 Apr 29. pii: S1473-3099(20)30366.
PubMed

LOHSE S, Pfuhl T, Berko-Gottel B, Rissland J, et al
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people.
Lancet Infect Dis. 2020 Apr 28. pii: S1473-3099(20)30362.
PubMed

SUN K, Viboud C
Impact of contact tracing on SARS-CoV-2 transmission.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30357.
PubMed

NEGIDA A
Estimation of COVID-19 burden in Egypt.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30329.
PubMed

SAHMOUD T
Estimation of COVID-19 burden in Egypt.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30318.
PubMed

BI Q, Wu Y, Mei S, Ye C, et al
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30287.
PubMed Abstract available

HASSANY M, Abdel-Razek W, Asem N, AbdAllah M, et al
Estimation of COVID-19 burden in Egypt.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30319.
PubMed

ELMELEEGY K
Estimation of COVID-19 burden in Egypt.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30321.
PubMed

TUITE AR, Ng V, Rees E, Fisman D, et al
Estimation of COVID-19 burden in Egypt - Authors' reply.
Lancet Infect Dis. 2020 Apr 27. pii: S1473-3099(20)30326.
PubMed

YU N, Li W, Kang Q, Zeng W, et al
No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy.
Lancet Infect Dis. 2020 Apr 22. pii: S1473-3099(20)30320.
PubMed

WINTER AK, Hegde ST
The important role of serology for COVID-19 control.
Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30322.
PubMed

VALETTE X, du Cheyron D, Goursaud S
Mediastinal lymphadenopathy in patients with severe COVID-19.
Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30310.
PubMed

YONG SEF, Anderson DE, Wei WE, Pang J, et al
Connecting clusters of COVID-19: an epidemiological and serological investigation.
Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30273.
PubMed Abstract available

HARGREAVES S, Zenner D, Wickramage K, Deal A, et al
Targeting COVID-19 interventions towards migrants in humanitarian settings.
Lancet Infect Dis. 2020 Apr 21. pii: S1473-3099(20)30292.
PubMed

WELLS CR, Fitzpatrick MC, Sah P, Shoukat A, et al
Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA.
Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30315.
PubMed

GABORIT BJ, Bergmann JF, Mussini C, Arribas JR, et al
Plea for multitargeted interventions for severe COVID-19.
Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30312.
PubMed

MODJARRAD K, Kim JH
Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?
Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30317.
PubMed

FOLEGATTI PM, Bittaye M, Flaxman A, Lopez FR, et al
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30160.
PubMed Abstract available

KOCH T, Dahlke C, Fathi A, Kupke A, et al
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30248.
PubMed Abstract available

NELSON R
COVID-19 disrupts vaccine delivery.
Lancet Infect Dis. 2020 Apr 17. pii: S1473-3099(20)30304.
PubMed

GLYNN JR
Protecting workers aged 60-69 years from COVID-19.
Lancet Infect Dis. 2020 Apr 16. pii: S1473-3099(20)30311.
PubMed

BENEZIT F, Le Turnier P, Declerck C, Paille C, et al
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19.
Lancet Infect Dis. 2020 Apr 15. pii: S1473-3099(20)30297.
PubMed

MEYER JP, Franco-Paredes C, Parmar P, Yasin F, et al
COVID-19 and the coming epidemic in US immigration detention centres.
Lancet Infect Dis. 2020 Apr 15. pii: S1473-3099(20)30295.
PubMed

XYDAKIS MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, et al
Smell and taste dysfunction in patients with COVID-19.
Lancet Infect Dis. 2020 Apr 15. pii: S1473-3099(20)30293.
PubMed

MARTINEZ-PORTILLA RJ, Gonce A, Hawkins-Villarreal A, Figueras F, et al
A Spanish-translated clinical algorithm for management of suspected SARS-CoV-2 infection in pregnant women.
Lancet Infect Dis. 2020 Apr 9. pii: S1473-3099(20)30285.
PubMed

KUCHARSKI AJ, Eggo RM
Invisible spread of SARS-CoV-2 - Authors' reply.
Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(20)30275.
PubMed

ZHANG W, Qian BY
Making decisions to mitigate COVID-19 with limited knowledge.
Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(20)30280.
PubMed

XIONG N, Wang T, Lin Z
Invisible spread of SARS-CoV-2.
Lancet Infect Dis. 2020 Apr 7. pii: S1473-3099(20)30263.
PubMed

RICHARDSON PJ, Corbellino M, Stebbing J
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30270.
PubMed

FAVALLI EG, Biggioggero M, Maioli G, Caporali R, et al
Baricitinib for COVID-19: a suitable treatment?
Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262.
PubMed

DEVI S
US public health budget cuts in the face of COVID-19.
Lancet Infect Dis. 2020;20:415.
PubMed

March 2020

POLAND GA
SARS-CoV-2: a time for clear and immediate action.
Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30250.
PubMed

SPYCHALSKI P, Blazynska-Spychalska A, Kobiela J
Estimating case fatality rates of COVID-19.
Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30246.
PubMed

KIM DD, Goel A
Estimating case fatality rates of COVID-19.
Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30234.
PubMed

LIPSITCH M
Estimating case fatality rates of COVID-19.
Lancet Infect Dis. 2020 Mar 31. pii: S1473-3099(20)30245.
PubMed

VERITY R, Okell LC, Dorigatti I, Winskill P, et al
Estimates of the severity of coronavirus disease 2019: a model-based analysis.
Lancet Infect Dis. 2020 Mar 30. pii: S1473-3099(20)30243.
PubMed Abstract available

RAJGOR DD, Lee MH, Archuleta S, Bagdasarian N, et al
The many estimates of the COVID-19 case fatality rate.
Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30244.
PubMed

LESCURE FX, Bouadma L, Nguyen D, Parisey M, et al
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30200.
PubMed Abstract available

JOYNT GM, Wu WK
Understanding COVID-19: what does viral RNA load really mean?
Lancet Infect Dis. 2020 Mar 27. pii: S1473-3099(20)30237.
PubMed

HUANG Y, Cheng W, Zhao N, Qu H, et al
CT screening for early diagnosis of SARS-CoV-2 infection.
Lancet Infect Dis. 2020 Mar 26. pii: S1473-3099(20)30241.
PubMed

SHI H, Han X, Cao Y, Alwalid O, et al
CT screening for early diagnosis of SARS-CoV-2 infection - Authors' reply.
Lancet Infect Dis. 2020 Mar 26. pii: S1473-3099(20)30247.
PubMed

TUITE AR, Ng V, Rees E, Fisman D, et al
Estimation of the COVID-19 burden in Egypt through exported case detection.
Lancet Infect Dis. 2020 Mar 26. pii: S1473-3099(20)30233.
PubMed

QIU H, Wu J, Hong L, Luo Y, et al
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.
Lancet Infect Dis. 2020 Mar 25. pii: S1473-3099(20)30198.
PubMed Abstract available

LUO Y, Yin K
Management of pregnant women infected with COVID-19.
Lancet Infect Dis. 2020 Mar 24. pii: S1473-3099(20)30191.
PubMed

YU N, Li W, Kang Q, Xiong Z, et al
Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.
Lancet Infect Dis. 2020 Mar 24. pii: S1473-3099(20)30176.
PubMed Abstract available

TUITE AR, Ng V, Rees E, Fisman D, et al
Estimation of COVID-19 outbreak size in Italy.
Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30227.
PubMed

LIU Y, Yan LM, Wan L, Xiang TX, et al
Viral dynamics in mild and severe cases of COVID-19.
Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30232.
PubMed

SCHMID MB, Fontijn J, Ochsenbein-Kolble N, Berger C, et al
COVID-19 in pregnant women.
Lancet Infect Dis. 2020 Mar 17. pii: S1473-3099(20)30175.
PubMed

BAUD D, Giannoni E, Pomar L, Qi X, et al
COVID-19 in pregnant women - Authors' reply.
Lancet Infect Dis. 2020 Mar 17. pii: S1473-3099(20)30192.
PubMed

THE LANCET INFECTIOUS DISEASES
COVID-19, a pandemic or not?
Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(20)30180.
PubMed

BAUD D, Qi X, Nielsen-Saines K, Musso D, et al
Real estimates of mortality following COVID-19 infection.
Lancet Infect Dis. 2020 Mar 12. pii: S1473-3099(20)30195.
PubMed

HAN H, Luo Q, Mo F, Long L, et al
SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients.
Lancet Infect Dis. 2020 Mar 12. pii: S1473-3099(20)30174.
PubMed

KUCHARSKI AJ, Russell TW, Diamond C, Liu Y, et al
Early dynamics of transmission and control of COVID-19: a mathematical modelling study.
Lancet Infect Dis. 2020 Mar 11. pii: S1473-3099(20)30144.
PubMed Abstract available

ZHOU C, Gao C, Xie Y, Xu M, et al
COVID-19 with spontaneous pneumomediastinum.
Lancet Infect Dis. 2020 Mar 9. pii: S1473-3099(20)30156.
PubMed

WILDER-SMITH A, Chiew CJ, Lee VJ
Can we contain the COVID-19 outbreak with the same measures as for SARS?
Lancet Infect Dis. 2020 Mar 5. pii: S1473-3099(20)30129.
PubMed Abstract available

XIAO Y, Torok ME
Taking the right measures to control COVID-19.
Lancet Infect Dis. 2020 Mar 5. pii: S1473-3099(20)30152.
PubMed

YAN G, Lee CK, Lam LTM, Yan B, et al
Covert COVID-19 and false-positive dengue serology in Singapore.
Lancet Infect Dis. 2020 Mar 4. pii: S1473-3099(20)30158.
PubMed

THANH HN, Van TN, Thu HNT, Van BN, et al
Outbreak investigation for COVID-19 in northern Vietnam.
Lancet Infect Dis. 2020 Mar 4. pii: S1473-3099(20)30159.
PubMed

FAVRE G, Pomar L, Qi X, Nielsen-Saines K, et al
Guidelines for pregnant women with suspected SARS-CoV-2 infection.
Lancet Infect Dis. 2020 Mar 3. pii: S1473-3099(20)30157.
PubMed

THE LANCET INFECTIOUS DISEASES
Challenges of coronavirus disease 2019.
Lancet Infect Dis. 2020;20:261.
PubMed

BURKI T
Outbreak of coronavirus disease 2019.
Lancet Infect Dis. 2020;20:292-293.
PubMed

BASTOLA A, Sah R, Rodriguez-Morales AJ, Lal BK, et al
The first 2019 novel coronavirus case in Nepal.
Lancet Infect Dis. 2020;20:279-280.
PubMed

LI J, Li JJ, Xie X, Cai X, et al
Game consumption and the 2019 novel coronavirus.
Lancet Infect Dis. 2020;20:275-276.
PubMed

February 2020

HUANG R, Xia J, Chen Y, Shan C, et al
A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China.
Lancet Infect Dis. 2020 Feb 28. pii: S1473-3099(20)30147.
PubMed

CHEN L, Xiong J, Bao L, Shi Y, et al
Convalescent plasma as a potential therapy for COVID-19.
Lancet Infect Dis. 2020 Feb 27. pii: S1473-3099(20)30141.
PubMed

STEBBING J, Phelan A, Griffin I, Tucker C, et al
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Feb 27. pii: S1473-3099(20)30132.
PubMed

LEE EYP, Ng MY, Khong PL
COVID-19 pneumonia: what has CT taught us?
Lancet Infect Dis. 2020 Feb 24. pii: S1473-3099(20)30134.
PubMed

PAN Y, Zhang D, Yang P, Poon LLM, et al
Viral load of SARS-CoV-2 in clinical samples.
Lancet Infect Dis. 2020 Feb 24. pii: S1473-3099(20)30113.
PubMed

SHI H, Han X, Jiang N, Cao Y, et al
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.
Lancet Infect Dis. 2020 Feb 24. pii: S1473-3099(20)30086.
PubMed Abstract available

PAN X, Chen D, Xia Y, Wu X, et al
Asymptomatic cases in a family cluster with SARS-CoV-2 infection.
Lancet Infect Dis. 2020 Feb 19. pii: S1473-3099(20)30114.
PubMed

XU B, Kraemer MUG
Open access epidemiological data from the COVID-19 outbreak.
Lancet Infect Dis. 2020 Feb 19. pii: S1473-3099(20)30119.
PubMed

DONG E, Du H, Gardner L
An interactive web-based dashboard to track COVID-19 in real time.
Lancet Infect Dis. 2020 Feb 19. pii: S1473-3099(20)30120.
PubMed

CHEN X, Tian J, Li G, Li G, et al
Initiation of a new infection control system for the COVID-19 outbreak.
Lancet Infect Dis. 2020 Feb 18. pii: S1473-3099(20)30110.
PubMed

VAN CUONG L, Giang HTN, Linh LK, Shah J, et al
The first Vietnamese case of COVID-19 acquired from China.
Lancet Infect Dis. 2020 Feb 18. pii: S1473-3099(20)30111.
PubMed

THOMPSON R
Pandemic potential of 2019-nCoV.
Lancet Infect Dis. 2020 Feb 7. pii: S1473-3099(20)30068.
PubMed

BAGCCHI S
Mysterious pneumonia in China.
Lancet Infect Dis. 2020;20:173.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.